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 ABSTRACT 
 
One in three adults over 85 years old suffer from Alzheimer’s disease (AD) or 
other forms of dementia. This already widespread condition is expected to increase 
further in both incidence and prevalence in coming years. As a result, the need to 
understand the etiology and pathogenesis of dementia becomes ever more urgent. AD, 
in addition to its steep cost of care, is the most common form of dementia and the 
sixth leading cause of death in the United States. It is a complex disease and its 
mechanisms are poorly understood. The more we learn about AD, the more questions 
are raised about our current conceptual models of disease. Despite the rapid 
advancement of medical technology, reliable and sensitive diagnostic markers to 
identify individuals at risk to AD prior onset of clinical symptoms remain in the 
developmental phase resulting in inefficient diagnostic procedures. Diagnosis is 
further hampered by the heterogeneity of behavioral presentations, cognitive 
impairments, and functional statuses observed in AD, all of which may be the result of 
varying etiologies. Furthermore, older AD patients often suffer from comorbid 
medical conditions that further complicate accurate disease monitoring. 
In the absence of an effective AD treatment, it is prudent to apply our current 
knowledge of the intersection between AD, cardiovascular disease (CVD), and 
cerebrovascular disease to foster efforts to delay the onset of dementia more generally. 
The purpose of MANUSCRIPT I is to review our current understanding of the 
epidemiology, genetics, and pathophysiology of AD as well as the intersection 
between AD and vascular causes of dementia.  The epidemiology and shared risk 
 factors and etiologies for these three disease “clusters” are explored, including shared 
genetic contributions and lifestyle, behavioral and environmental risk factors.  In this 
first publication, we also explore possible mechanistic pathways of AD and the shared 
pathophysiology and neuropathological substrates of these three disease clusters.  
CVD and cerebrovascular pathology is present for most individuals with AD, 
although the converse is not necessarily true. Given this relationship, it is important to 
address how early in the disease course those vascular changes can be observed. Such 
research is needed to enable early interventions to maintain quality of life in 
premorbid AD and reduce the burden of disease.  To determine whether there is 
cardiovascular alteration in the early stages of AD, MANUSCRIPT II evaluated 
electrocardiologic measures of vagal tone for 63 adults (ages 55-75) at rest, during 
cognitive testing, and then again at rest. All subjects had multiple risk factors for AD, 
and all completed amyloid PET scans (18F-Florbetapir) to determine amyloid 
positivity (Aβ+). Cardiac autonomic dysfunction, specifically, an increase in 
sympathetic activity and a decrease in parasympathetic activity often referred to as 
vagal withdrawal, is prevalent among individuals with AD and is indicative of 
impaired autonomic function.  
Preclinical AD participants (Florbetapir amyloid PET SUVr ≥ 1.1) did not 
consistently show changes in vagal ratio or Respiratory Sinus Arrhythmia (RSA) at 
any point during the experiment and they failed to demonstrate the expected response 
to the modest stress they experienced during cognitive task performance.  Both 
changes are directly modulated by both muscarinic and nicotinic cholinergic 
autonomic neurotransmission. Because the earliest stages of AD are marked, in part, 
 by altered function of the basal forebrain cholinergic system, with eventual 
degenerative changes including neuronal loss, this result suggests a link between Aβ 
aggregation and impaired autonomic cardiovascular function, even in the preclinical 
stage of AD. 
Another factor that influences the lack of treatment is the absence of a reliable, 
affordable, and sensitive diagnostic marker to identify individuals at risk for AD 
before the onset of clinical symptoms. One possible marker may be found in the 
retina, the retina shares similar embryological origins, anatomical features, and 
physiological characteristics with the brain. From as early as the fourth week of 
gestation, the eyes, particularly the retinal nerve fiber layer (RNFL) and the optic 
nerve, are direct sensory extensions of the central nervous system as their axons 
synapse directly with several brain regions.  Unlike the brain, however, retinal 
neuronal cell layers can be non-invasively visualized through high-resolution optical 
methods such as optical coherence tomography (OCT) allowing for the precise 
segmentation and measurement of these cell layers. For MANUSCRIPT III, more 
than 15 years of literature with inconsistent findings on the relationship between the 
morphology of retinal neuronal layers and AD were reviewed. Most papers reported 
RNFL and ganglion cell layer (GCL) thickness to be significantly reduced in cross 
sectional studies of patients with mild cognitive impairment (MCI) and mild to 
moderate AD.  For the first time, this Manuscript explores within-subjects longitudinal 
change in retinal morphology during the preclinical stage of AD for all retinal 
neuronal layers. For this manuscript, fifty-six older adult participants (mean age = 
65.36 years) from the previous manuscript completed Spectral Domain-OCT retinal 
 imaging at baseline. Twenty-seven months later, they completed the same exams as 
well as an 18F-Florbetapir PET imaging and cognitive testing.  
We observed a decrease over time in macular RNFL, outer nuclear layer and 
inner plexiform layer volumes in preclinical AD relative to controls. While the 
macular region of the retina is physiologically very active in healthy normal eyes, this 
region might have diminished activity in the preclinical stage of AD. This thinning 
could be due to either demyelination or loss of axons in the RNFL, both of which 
suggest the possibility of future degenerative changes to the cell bodies in the GCL 
followed by progression to deeper neuronal layers. Volume loss in the RNFL, during 
the preclinical stage, is not related to performance on measures of episodic memory or 
problem solving. However, this retinal change does appear to be modestly related to 
relative decrements in performance on a measure of audiovisual integration efficiency 
that has been recently advanced as a possible early cognitive marker of mild cognitive 
impairment. 
In order to tie together the findings of relative changes in cardiovascular 
function and retinal morphological changes in preclinical AD, we decided to utilize 
optical coherence tomography angiography (OCTA), a new technology that makes it 
possible to measure retinal vascular flow.  Recently, a reduction in vascular bed 
complexity in MCI and AD relative to healthy controls was reported by using a fractal 
dimension (Df) approach to summarizing OCTA imaging results. In MANUSCRIPT 
IV, forty-eight adults (mean age = 68.76 years) from the same sample of participants 
had retinal OCTA images captured using an AngioVue system (Optovue, Fremont, 
CA, USA). The Df was measured in linearized images of the superficial vascular 
 plexus (SVP) to determine the space-filling linear extension of the large vessels. Our 
findings suggest that individuals at high-risk for preclinical AD have less density and 
complexity of retinal microvascular networks in the SVP of the macular region (the 
same region in which structural changes were observed in Manuscript III) than healthy 
controls. Reduced vascular density in the SVP likely leads to degradation in blood 
flow throughout the other parts of the retina and therefore might directly contribute to 
continued axonal loss as well as future GCL thinning in AD. Retinal vascular 
distribution and blood flow were found to be altered during the earliest stages of AD 
suggesting a potential cost-effective and non-invasive marker for preclinical AD.  
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Abstract  
As the population ages due to demographic trends and gains in life expectancy, the 
incidence and prevalence of dementia increases, and the need to understand the 
etiology and pathogenesis of dementia becomes ever more urgent. Alzheimer’s disease 
(AD), the most common form of dementia, is a complex disease, the mechanisms of 
which are poorly understood. The more we learn about AD, the more questions are 
raised about our current conceptual models of disease. In the absence of a cure or the 
means by which to slow disease progress, it may be prudent to apply our current 
knowledge of the intersection between AD, cardiovascular disease, and 
cerebrovascular disease to foster efforts to delay or slow the onset of AD. This review 
discusses our current understanding of the epidemiology, genetics, and 
pathophysiology of AD, the intersection between AD and vascular causes of dementia, 
and proposes future directions for research and prevention  
 
Keywords 
 Alzheimer’s disease; Cardiovascular disease; Cerebrovascular disease; Vascular 
contributions to cognitive impairment and dementia; VCID; Dementia; Risk factors  
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Research-in-Context 
 
Systematic Review:  The authors conducted online searches for all the relevant 
literature describing the relationship between Alzheimer’s disease (AD), 
cardiovascular (CVD) and cerebrovascular diseases (CBVD). A thorough review of 
common epidemiology, risk factors, and possible mechanic pathways that might link 
these three entities, is provided.  
 
Interpretation:  There is a substantial overlap in epidemiologic, genetic, and clinical 
literature of shared risk factors for AD and cardio- and cerebro-vascular co-
morbidities.  There is also very substantial overlap in shared mechanistic relationships 
between AD and both CVD and CBVD. We suggest that vascular/cerebrovascular 
pathology is present for most individuals with AD, although the converse is not 
necessarily true). 
 
Future Directions: Further investigation is required to understand the mechanistic 
pathways for shared pathology between these two constellations of diseases.  Our 
group and others are tracking vascular changes in preclinical AD patients. 
Epidemiological studies of CVD progression promise new insights on the effects of 
subclinical CVD on the brain.  Currently ongoing cardiovascular prevention trials 
impacting dementia risk will provide substantial insight into the possibility of delaying 
the onset of AD.   
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General Introduction 
 
One of the greatest advancements of health in the 20th century was an increase 
in average life expectancy by 30 years [1]. Today, people aged 85 and older are the 
fastest growing segment of the population and this has led to a new set of problems for 
modern healthcare as the elderly are the most susceptible to disease and disability. 
One in three adults over 85 years old suffer from Alzheimer’s disease (AD) or other 
forms of dementia [2], the prevalence of which is estimated to increase dramatically 
over the next 40 years unless preventive measures are developed [3].  AD is currently 
the sixth leading cause of death in the United States and the cost of the disease is high. 
Approximately $236 billion will be spent on AD during 2016 calendar year overall, 
including patient care and caregivers’ lost wages [4].   
Despite the global increase of both incidence and prevalence of AD, it is the 
only leading cause of death that we are currently unable to prevent or cure [5]. The 
remarkable heterogeneity of risk factors, etiologies, and neuropathologic processes 
associated with AD make it especially challenging for development of new treatments 
to slow disease progression [4,6].  Fortunately, a number of experimental therapies are 
currently in development.  These are aimed at mechanisms including 
neurotransmission regulators, tau-based therapies, amyloid-β based strategies, 
intracellular signaling cascade modulators, oxidative stress reductors, mitochondrial 
target therapy, cellular calcium homeostasis modulators, and anti-inflammatory 
therapies [7,8,9,10,11]. It is possible that the heterogeneity of behavioral presentations, 
cognitive impairments, and functional status observed in AD is due to its potentially 
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varied etiology [12].   Adding to this complexity, older adults with AD typically 
present with comorbid medical conditions that further complicate accurate disease 
monitoring [13].  The current dominant AD models are insufficient to account for the 
complexity of biologic processes, polygenic, and epigenetic factors at work [14]. As a 
result, key opinion leaders have suggested that the field would benefit from the 
development of new conceptual models of AD [14].  The purpose of this review is to 
explore the complex relationship between AD, cardiovascular disease (CVD) and 
cerebrovascular disease (CBVD). Recent reports that question the strength of the 
association between these disease entities will be reviewed and recommendations will 
be made for additional research questions to more precisely characterize causal links 
between AD, CVD, and CBVD.   
 
Shared Genetic Contributions to AD and Cardiovascular Disease. 
The genetic contribution to AD risk is complex.  Three familial autosomal 
dominant genes associated with early onset disease have been discovered (PSEN1, 
PSEN2 and APP) [15,16,17,18,19,20], and these genes may also be associated with 
some later onset cases; although together they likely account for less than 10% of all 
AD cases [21].  The most predominant type of AD is Late-Onset Alzheimer’s Disease 
(LOAD, referred to herein as AD), which affects adults in their sixth to eighth decade 
of life.  While many genetic risk factors for AD have been studied, a definitive 
genotype that causes (late onset) AD has not yet been identified  [22].  Thus far, few 
genetic markers have been linked to both risk of AD and CVD or CBVD risk. The 
ε4 allele of the Apolipoprotein E (APOE) gene is a risk factor for both AD and CVD. 
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Over the past two decades, numerous studies have shown that individuals who carry at 
least one copy of the ε4 allele have an increased risk for AD compared to those 
without the ε4 allele [23,24,25,26] and ε4 carriers with AD have lower blood levels of 
ApoE [27].  Low plasma levels of ApoE protein have been found to increase the risk 
of AD independent of APOE genotype [28].  
Two polymorphisms (rs1801133, rs1801131) in the methylenetetrahydrofolate 
reductase (MTHFR) gene correlate with elevated levels of plasma homocysteine and 
appear to be associated with AD and vascular contributions to cognitive impairment 
and dementia (VCID) [29,30].  High plasma homocysteine levels have been identified 
as a risk factor for VCID in a Northern Irish population [29]. Mutations in the MTHFR 
gene were found to increase the risk of AD by 2.5 fold and VCID by 3.7 fold in an 
Asian population [30].   
Beyond APOE and MTHFR, few other genes have been identified to 
significantly increase the risk of both AD and CVD. Genetic associations with smaller 
effects have been found but a detailed discussion of these is beyond the scope of this 
review.  Recently, new approaches to evaluating genetic pleiotropy in complex 
diseases have been developed [31].  These methods are now being applied to AD [32] 
and one recent study demonstrated genetic overlap between AD and CVD by 
conditioning on CVD phenotypes including C-protein reactive (CRP) and plasma 
lipids [33].  
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Shared Risk Factors for AD and CVD 
AD and CVD share important cardiometabolic and lifestyle risk factors that 
occur in middle-aged to elderly populations.  Both AD and CVD are associated with 
increasing age, and both are among the leading causes of death.  The primary causes 
of CVD are coronary heart disease (CHD), hypertension, stroke, and heart failure. 
These diseases are frequently interconnected and share an underlying pathology of 
atherosclerosis. All known risk factors for atherosclerosis have been the focus of 
studies to identify modifiable risk factors for AD.  Researchers from the Framingham 
Heart Study [34,35] developed a composite measure of general cardiovascular risk, the 
Framingham Cardiovascular Risk Profile (FCRP), derived by evaluating one’s age, 
gender, diabetes, smoking, treated and untreated systolic blood pressure (SBP), total 
cholesterol, and high density lipoprotein (HDL) cholesterol [36]. In addition to 
increased risk of CVD, an elevated FCRP score on has been related to markers of 
abnormal brain aging, such as smaller brain volume and increased white matter 
hyperintensities in brain imaging exams [37]. High FCRP scores are associated with 
worsening of cognitive abilities, both in cognitively intact subjects and in mild 
cognitive impairment (MCI) patients [38] and is a reliable predictor of progression 
from MCI to AD [39].  Other scores developed from Framingham, the Framingham 
Stroke Risk Profile and the Framingham Coronary Heart Disease Risk Score, have 
been similarly associated with cognitive change over time, incident cognitive 
impairment, and dementia [35,39,40,41,43,44].  These risk models are similar to one 
developed specifically to assess dementia risk, the Cardiovascular Risk Factors Aging 
and Dementia (CAIDE) risk score [45,46,47].  Common elements across scores are: 
 9 
 
blood pressure, cholesterol, and diabetes.  Below, we review elements of these risk 
scores as they relate to both CVD and AD. 
 
Hypertension /Hypotension  
Chronic hypertension, a common risk factor for CVD, causes a thickening of 
vessel walls, reduced vessel elasticity and the narrowing of the lumen, especially in 
small vessels [48,49]. These sequelae result in reduced cerebral blood flow, a 
prominent step in the pathophysiology of both AD and CVD. Chronic hypertension 
also compromises blood-brain barrier (BBB) integrity, leading to both cerebral edema 
and the introduction of systemic elements into the brain parenchyma [50]. 
Hypertension recorded 15 years prior, has been associated with smaller brain volumes 
in areas typically affected by AD such as the hippocampus [51].  Our group has 
observed that an increased resting-state cardiac rate pressure product (RPP) as a 
surrogate of myocardial oxygen use, has a small to moderate correlation with 
neocortical amyloidosis in midlife adults with preclinical AD [52].    
Epidemiological studies have shown that hypertension is risk factor for 
dementia [53,54, 55,56,57] but the association is complex [58].  Studies have found 
that the risk of dementia and AD may vary in strength and direction according to the 
age of onset [55,56,59,60].   Further complicating these findings, several studies have 
demonstrated that antihypertensive drugs can reduce the risk of AD [61,62,63,64,65].  
Diuretic, angiotensin receptor-1 blocker, or angiotensin-converting enzyme inhibitor 
use in the Ginkgo Evaluation of Memory Study, was associated with a reduced risk for 
MCI and AD [62].  Among 2,197 participants from the Honolulu-Asia Aging Study 
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who were dementia free at baseline, beta-blocker users experienced a 31% lower risk 
of developing new cognitive impairments of any cause, compared to those with other 
antihypertensive or no antihypertensive use [63]. Taken together, these findings 
suggest that methods to effectively lower BP in midlife, e.g., lifestyle changes or 
medications, should help retain or improve cognitive function by reducing the risk of 
AD and/or VCID.   
Conversely, there is evidence demonstrating that hypotension in late life is closely 
associated with a higher risk of AD.  The Bronx Aging Study [66] followed a healthy 
cohort of older adults aged ≥75 years over a median follow up of 6.7 years. 
Participants with diastolic blood pressure (DBP) <70 mmHg were twice as likely to 
develop AD as those with DBP >90 mmHg, and this risk was even higher for subjects 
with persistently low DBP. Interestingly, there was no such relationship for SBP, and 
the association between diastolic hypotension and AD was specific; no such 
association existed for VCID.  A pooled analysis of data from the Rotterdam Study (N 
= 6,668) and the Gothenburg H-70 Study (N = 317) found baseline diastolic 
hypotension was associated with higher risk of AD and/or VCID over an average of 
2.1 years of follow-up, and that the risk was more pronounced in antihypertensive 
medication users [57]. Another population-based study (N = 599, mean age 83.5 
years) similarly revealed that lower DBP and SBP were associated with a higher 
incidence of AD [67]. Extremely low DBP (≤65 mmHg) produced an adjusted relative 
risk of 1.7 (95% CI 1.1-2.4) for AD in a prospective study of 1,270 individuals aged 
75-101 years [68].  Finally, a meta-analysis of 20 population based studies revealed 
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that a decline in DBP in later life may contribute to diminished cerebral perfusion, and 
the subsequent ischemic state may lead to increased cerebral Aβ accumulation [69]. 
 
High Cholesterol 
Cholesterol metabolism plays an important role in the central nervous system 
(CNS), as the brain is a cholesterol rich organ, comprising 25% of the body’s 
cholesterol [70]. Studies have indicated that lipoprotein lipase, an enzyme that 
hydrolyzes triglycerides, may be involved in the biological basis of both AD and CVD 
(e.g. essential hypertension, CHD) [71,72,73]  through its interaction with brain 
lipoproteins and modulation of cholesterol homeostasis in neuronal cells [74]. 
Apolipoprotein E is crucial for the catabolism of triglyceride rich lipoprotein 
components and for cholesterol transport [75] Cholesterol supplied as a lipoprotein 
complex, such as HDL is critical for the maturation of synapses and the maintenance 
of synaptic plasticity [76,77]. Cholesterol levels influence the clearance of Aβ and the 
formation of neurofibrillary tangles through action at the lipid rafts located in neuronal 
membranes.  
Outside the brain, atherosclerosis is a frequent consequence of high cholesterol 
and is an important risk factor for ischemic cerebrovascular disease [78].  The 
contribution of atherosclerosis, a frequent consequence of high cholesterol, is an 
important risk factor for ischemic cerebrovascular disease [78].  APOE Ɛ4 carrier 
status is both a risk marker for AD and CVD. In the Rotterdam Study, APOE Ɛ4 
carriers with atherosclerosis frequently had co-morbid AD and more frequent co-
morbid VCID [79,80].   
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Elevated total serum cholesterol levels have been associated with MCI and AD 
risk in some studies [81,56].  Others have found that the association between 
cholesterol and AD is complex [82,83].  Similar to hypertension, the risk of dementia 
associated with high cholesterol may be influenced by the timing and duration of the 
condition, as well as its treatment. One reason for this complexity is that plasma 
cholesterol levels do not reflect cholesterol concentrations inside the BBB.  The 
association between high cholesterol and increased risk of AD has resulted in a 
number of studies testing the hypothesis that statins, which play a role in cholesterol 
reduction, might prevent the onset or progression of AD.  Early epidemiological 
studies in this area predicted that statins could reduce the incidence of AD by as much 
as 70% [84,85,86].  However, whether statins and resultant reduction of cholesterol 
cause a significant reduction in AD pathology is still unclear.  More recent results of 
large-scale randomized controlled trials suggest no significant clinical benefit of 
statins in participants at-risk for AD [87,88]. 
 
Diabetes Mellitus 
Diabetes mellitus (DM) is a complex metabolic disorder that is closely 
associated with changes in cognition as well as other risk factors for accelerated 
cognitive decline and dementia, such as hypertension and atherosclerosis [89].  DM 
occurs when there is a prolonged period of high blood glucose levels, or 
hyperglycemia.  There are two types of DM, Type 1 is congenital and caused by 
insulin deficiency, and Type 2 is acquired and caused by insulin resistance.   
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Although there are points of intersection between the molecular mechanisms 
underlying diabetes and AD, the exact mechanism of how insulin inefficiency 
increases the risk of AD remains unknown. The literature is currently separated into 
two different schools of thought [90]. One follows from Rotterdam study findings, 
suggesting that the excess of insulin or glucose from type 2 diabetes mellitus (T2DM) 
leads to AD. This is based on studies demonstrating that AD patients have 
significantly higher levels of insulin and glucose than healthy controls [91,92,93]. A 
second school of thought suggests that insulin deficiency, either due to the relative 
deficiency that results from insulin resistance in early stages of T2DM, or absolute 
deficiency that occurs when beta cell dysfunction occurs in full-blown T2DM, causes 
AD by impairing insulin’s ability to perform its roles in the brain [94,95,96,97]. 
In addition to these two theoretical approaches in the literature, some have 
suggested the term “Type 3 diabetes” was coined to account specifically for the 
underlying abnormalities associated with concurrent AD-type neurodegeneration and 
diabetes [98]. These researchers maintain that AD and diabetes share common 
pathophysiology, and therefore therapeutic regimes aimed at diabetes treatment and 
amelioration could be effective for treatment of AD [99].  
A recent meta-analysis demonstrated a strong link between diabetes and VCID 
[100].  Findings from the Rotterdam study demonstrated a nearly two-fold risk of AD 
and suggest that DM increases the risk of dementia by 1.9 fold, and that DM patients 
treated with insulin were at even greater risk (4.3 fold) [101].   Multiple population-
based studies have shown that patients with DM exhibit an increased risk of 
developing AD [102, 103, 104, 98].  The authors of one such study concluded that 
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39% of AD in a large sample of elderly subjects was attributable to hyperinsulinemia 
or DM [105]. 
As with other CVD risk factors, treatment for diabetes has been shown to alter 
the risk of AD.  Metformin has been shown to reduce the risk of AD and is currently 
being studied in clinical trials with promising preliminary results in MCI patients 
[106]. A large clinical trial is currently underway to evaluate the efficacy of low dose 
pioglitazone as a preventive treatment for MCI due to AD [107].  Other studies have 
considered the use of intranasal insulin, which has been shown to exert a modest effect 
on memory performance in AD patients [108,109,110,111]. 
 
Lifestyle, Behavioral, and Environmental Risk Factors 
 High fat diets and sedentary lifestyles have led to a growing incidence of 
obesity, dyslipidemia, high blood pressure and metabolic syndromes [112, 113,114]. 
These conditions are precursors to, or develop along with atherosclerosis, diabetes, 
CVD, and an increased risk for AD [115].  Major depression has also been linked to 
both AD and CVD and more recently environmental exposures such as fungal 
pathogens and pollution have been under investigation for ties to both AD and CVD.  
Below, we review the literature that explores the obesity, aerobic exercise, smoking, 
major depression, and exposures such as fungal pathogens and air pollution, each as 
shared risk factors for both CVD/CBVD and AD. 
Obesity  
The mechanism by which obesity influences cognition and AD risk remains 
under active investigation. One mechanism may be through vascular pathologies, or 
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there may be hormonal, genetic, or inflammatory processes at work [116]. The 
Framingham Heart Study reported a marked impairment of cognitive function in 
patients with obesity compared with non-obese counterparts [117].  Epidemiological 
studies have shown associations between obesity and increased AD risk in females 
[118,119] although other studies have found increased risk of dementia for both 
genders [59]. Pooled results from 11 studies [120] demonstrated that the strength and 
direction of the association varies over the life course.  The association between body 
mass index (BMI) and later onset of AD appears to be stronger when BMI is measured 
at midlife [121] than when BMI is measured in later life [118,122].  Although they 
frequently co-occur, DM and obesity are widely accepted as important independent 
risk factors for AD [123].   
 
Aerobic exercise and physical fitness 
In contrast to metabolic syndromes, aerobic exercise and healthy lifestyles 
have been shown to reduce the incidence of both CVD and AD in observational 
studies.  Cardiovascular diseases have become very common as communities and 
individuals attain more wealth and pursue more sedentary lifestyles [123]. Aerobic 
exercise promotes brain vascularization and may reduce vascular risk factors and 
improve cognitive function [124,125,126,127]. Randomized controlled trials with as 
little as six months of exercise training lead to increased hippocampal volume and 
improved performance on spatial memory and executive function tasks [128,129].  
Aerobic exercise also up-regulates brain derived neurotrophic factor (BDNF), which 
augments plasticity in the hippocampus [130,131].  
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Epidemiological studies have demonstrated reduced risk of cognitive decline 
and dementia as a function of activity levels [132,133,134] and studies have shown 
increased gray and white matter volume in brains of participants assigned to aerobic 
training [135] or those with higher levels of self-reported exercise [136].   Recent 
meta-analysis of clinical trials of exercise interventions in dementia patients 
demonstrated positive effects [137].  A recent prevention trial of an exercise 
intervention in sedentary older adults failed to find a significant effect on cognitive 
function [138], however secondary analyses found significant improvement in 
cognitive function among the subset of participants who were diabetic [139].  
A related measure of physical fitness is heart rate variability (HRV) on 
continuous electrocardiography recordings.  HRV is usually relatively high for those 
who exercise frequently [140], as well as for young and healthy individuals.  Aging 
and poor physical fitness are associated with an impairment of cardiac vagal function 
[141], and HRV is lower for those with relatively diminished parasympathetic tone 
[142], including those with CVD [143].  Vagal tone, the ability of the vagus nerve to 
rapidly regulate cardiac output, accounts for a substantial portion of HRV.  Vagal tone 
can be quantified via respiratory sinus arrhythmia (RSA), which measures the slight 
ebb and flow in heart rate that occurs during the respiratory cycle. RSA is higher in 
older adults who demonstrate better performance on tasks of verbal episodic memory, 
a cognitive domain that is typically impaired with the onset of AD [144].   
In Table 1, we provide a listing of evidence-based interventions for the 
treatment of CVD, discussed in the sections above, and how these specific 
interventions have been explored in the treatment of AD.   
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------------------------------------------------------------ 
Insert Table 1 About Here 
  ------------------------------------------------------------- 
 
Smoking 
There is some evidence to suggest that long-term cigarette smoking is an 
independent risk factor for AD, CVD and CBVD [145,146,147].  Smoking increases 
total plasma homocysteine, an independent risk factor for stroke, cognitive 
impairment, AD and other dementias [148,149,150,151]. Smoking accelerates 
atherosclerosis [142] and can cause oxidative stress, which is associated with 
excitotoxicity, leading to neural death [152]. A dose-response relationship between 
smoking and dementia risk has been documented [153] and AD risk among smokers is 
increased in APOE ε4 carriers [101,154]. A meta-analysis of studies performed in the 
1990s and early 2000s revealed that relative to non-smokers, current smokers had 
increased risks of 1.79 fold (95% CI 1.43–2.23) for AD and 1.78 fold (95%CI 1.28–
2.47) for VCID [155]. A more recent systematic review confirmed the previous 
findings with increased risks of 1.59 fold (95% CI 1.15–2.20) for AD and 1.35 fold 
(95%CI 0.90–2.02) for VCID [156].   
 
Major Depression 
A history of major depression is another shared risk factor for AD and CVD.  
Late-onset depression is often associated with AD, and AD patients with episodes of 
major depression over their lifetimes show greater hippocampal pathology at autopsy 
[157]. Evidence exists to suggest that the two disorders may share common etiological 
substrates [158, 159].  Chronic, untreated major depressive disorder is associated with 
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the selective loss of noradrenergic cells in the locus coeruleus [160,161] and the loss 
of dorsal raphe serotonergic nuclei [162], both of which have been demonstrated in 
AD. Major Depression is now widely acknowledged to be a CHD risk factor, based on 
work demonstrating that psychosocial factors such as chronic dysphoria, anxiety, 
perceived loss of locus of control and perceived stress are strongly predictive of 
incident myocardial infarction [163]. Nearly one of five patients with CVD suffers 
from major depressive disorder [164].  Depression may be directly linked to cerebral 
ischemia secondary to reduced cerebral blood flow [164] and is associated with an 
increased risk of recurrent stroke in patients with VCID [165].  CVD has been 
proposed as a mediator of the relationship between major depression and AD [166]. 
Hyperhomocysteinemia has been demonstrated in both AD and major depression 
[167,168].  Adding to this already complex picture, heightened homocysteine levels 
are found in CVD [149], indicating a potential shared mechanism in AD, CVD, and 
major depression. The exact nature of the downstream effects of this mechanism 
requires further research.  
 
Fungal pathogens 
More recently, fungal macromolecules have been identified as a potential 
pathophysiological substrate of both AD and CVD. The presence of fungal cells in 
different sizes and hyphae inside capillaries and other blood vessels in some AD 
patients suggests that fungal infections can be detected in the neurovascular system 
and may, in some cases, explain the vascular pathology frequently detected in AD 
patients [169,170]. One study showed that Aβ peptide, a cardinal feature of AD 
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pathology, could exert antimicrobial activity for at least eight different 
microorganisms, suggesting a brain with AD could specifically induce Aβ-mediated 
inflammatory activity against Candida albicans [171]. Unfortunately, many 
macromolecules with antimicrobial activity have been shown to be cytotoxic towards 
vascular smooth muscle cells [172], and Aβ is no exception [173]. There is also 
association of AD with various types of spirochetes, and C. pneumonia [174]. 
However, thus far, to our knowledge, the only documented common fungal or 
microbial pathogenic link between AD and CVD is Candida albicans. The 
pathophysiological link between pneumonia and acute cardiovascular events has been 
explained via the long-lasting infection hypothesis, which implicates microorganisms 
in atherosclerosis [175].  
 
Air pollution 
 Chronic exposure to air pollution, which is associated with reduced HRV, is 
another environmental factor that is associated with both CVD and AD.  Specifically, 
long-term exposure to high ozone and high particulate matter in the air leads to 
increased risk for obesity, metabolic syndrome [176], and a host of CVDs [177} 
including myocardial ischemia and infarction, heart failure, arrhythmias, stroke, and 
increased cardiovascular mortality [178].  Recently, a dose-response relationship was 
found between longitudinal exposure to high concentrations of atmospheric particulate 
matter <10 μm in diameter and significantly increased risk of AD and VCID in 
industrial regions of Taiwan [179]. 
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Co-occurrence of AD and Cerebrovascular diseases 
Cerebrovascular disease (CBVD) is a generic term from a heterogeneous set of 
insults to the cerebral vasculature, and such insults often lead to various cognitive 
impairment(s). CBVD insults include, but are not limited to, microvascular 
degeneration (with looping, twining and braiding vessels) [180], periventricular 
venous collagenases, and vascular tortuosity [181]. These microvascular changes all 
cause impaired cerebral perfusion [182].  Some studies have shown a correlation 
between capillary length per brain volume and reduction of glucose utilization [183].  
Intracerebral hemorrhages due to Aβ accumulation within vessel walls can contribute 
to AD pathology [184]. This leads to increased incidence of infarcts in the brain tissue 
innervated by this system [185].  Collectively, these conditions are considered among 
the causes for VCID.  VCID (vascular contributions to cognitive impairment 
and dementia) refers to a progressive worsening of cognitive functions and memory.  
VCID is due exclusively to vascular disease within the brain [186]. It is often very 
difficult to distinguish AD from VCID as they appear very similar on clinical exam. 
VCID patients often present with episodic memory impairments, word-finding 
difficulties, disorientation to time, and subtle executive deficits [187]. Thus, a 
differential diagnosis is aided by careful neuropsychological examination in 
conjunction with appropriate biomarker studies [188]. 
In the United States, CBVD is the leading cause of disability in adults and the 
third leading cause of death [189]. CVD often plays a direct causal role in 
cerebrovascular events, as CBVD often results from a lack of blood flow to the brain. 
Various CBVD pathologies are observed in 60 to 90% of AD patients, including white 
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matter lesions, micro-infarcts, hemorrhages, microvascular degeneration and cerebral 
amyloid angiopathy (CAA) [75].  CAA is the abnormal deposition of a congophilic 
material in meningeal and cerebral arterioles.  The prevalence of CAA is high in AD 
and often progresses in severity causing vessel rupture [190].  Atherosclerosis, a 
common cause of CBVD, can lead to cerebral infarction or stroke, and disabling 
cognitive impairments in late life [191]. Many large population-based epidemiologic 
studies have provided strong support for the relationship between AD and 
cerebrovascular changes. One such study examining two large cohorts of AD patients 
found a strong relationship between AD and cerebral atherosclerosis, such that the 
presence of atherosclerosis was associated with worse cognitive performance in AD 
[192].  The Framingham Heart Study found that a lower cardiac index was associated 
with increased risk of AD [193].  These findings suggest that age-related changes in 
systemic hemodynamics may contribute to the pathogenesis or exacerbation of 
amyloid deposition, subsequent neuronal injury, and vascular pathology [193].  
Similar findings have been reported for other large epidemiologic studies, including 
the Pittsburgh Cardiovascular Health Study [194] and the Prospective Population 
Study of Women in Gothenburg, Sweden [195].  Likewise, the Atherosclerosis Risk in 
Communities (ARIC) study found a high prevalence of MRI-detected cerebral 
abnormalities, related to cognitive functioning, that might reflect preclinical AD [196]. 
As described above and across a large body of published literature, VCID can 
manifest solely as a result of CBVD events, such as hemorrhagic or ischemic strokes, 
or by the accumulation of multiple ischemic events. However, it remains unclear 
whether AD occurs in the absence of any vascular pathology, or whether CVD and 
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CBVD changes are mechanistically related to the fundamental pathology of AD.  Two 
separate imaging studies have recently cast doubt on the interdependence of AD and 
vascular pathologies [197,198].  The studies suggest that AD-related amyloid burden 
and CBVD independently affect cognitive impairment, as there was no correlation 
between the images comparing specific neuroanatomic coordinates of both 
amyloidosis (positron emission tomography (PET) PIB ligand binding) and white 
matter hyper intensities (WMH) with structural magnetic resonance imaging (MRI).  
In a study of 251 cognitively impaired subjects, Ye and colleagues found that PiB 
retention ratios were associated with both hippocampal atrophy and memory 
impairments and, conversely, the WMH imaging was more strongly associated with 
frontal cortex thinning and executive dysfunction.  The authors concluded that the 
effect on cognition for individuals with both pathologies was additive and not 
synergistic, thus, the impact of AD and CVD pathologies on cognition are mediated 
through independent mechanisms [198]. Vemuri et al (2015) evaluated MRI and PET 
images from 393 cognitively normal participants, aged 70 to 90 from the Mayo Clinic 
Study of Aging and showed that for subjects with both vascular and amyloid 
pathologies, the effect of both pathologies on cognition was additive and not 
synergistic [197]. Both Ye, and Vemuri and colleagues have put forward similar 
arguments, but they are based on a single MRI imaging marker of CBVD. However, 
as we outline below, cardio- and cerebrovascular pathologies are highly complex 
clusters of biological processes that share many points of mechanistic links to AD.  
These two recent imaging studies stand as outliers within a large body of literature 
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suggesting that although VCID may frequently occur in the absence of AD, the 
converse is not necessarily true.   
 
AD, CVD, & CBVD: Shared Pathophysiology and Neuropathological Substrates  
AD, CVD and CBVD, primarily affect the same at-risk population who share 
many common risk factors.  All three diseases may independently and/or inter-
dependently lead to debilitating, unremitting and progressive changes in cognition.  
The direct causal relationship between vascular and cerebrovascular insults, and 
dementia or apoplexia, was described over three centuries ago by Thomas Willis 
[199].  Medical practitioners generally considered dementia to result from vascular 
insults. As early as 1833 Lobstein used the term “dementia arteriosclerotica” 
attributing the nature of the disease to a vascular origin [200].  A causal link between 
other non-vascular brain disease states and dementia was not well described until the 
latter half of the 19th century.  In 1871, Charles Darwin received a letter from the 
director of England’s largest lunatic asylum, Dr. James Crichton-Browne, who 
observed that senile decay was the result of central nervous system disease that was 
linked to emotional liability [159]. Thirty-six years later, the initial case report of 
Alois Alzheimer’s; described the finding of senile plaques and neurofibrillary tangles 
found on post-mortem histopathology exam of a patient who had “ordinary dementia” 
and neuropsychiatric symptoms [201].  
Prof. Alzheimer presaged the complexity and multi-causality of dementia by 
reporting atherosclerosis in the cerebral blood vessels of his 55 year-old patient, for 
which he coined the term Alzheimer’s sclerosis [202]. The term AD was reserved for 
 24 
 
the diagnosis of dementia with onset between ages 40 and 90 years, if the other causal 
explanations (e.g., vascular causes) of dementia were absent [203].  The National 
Institute of Aging (NIA) and the Alzheimer’s Association (AA) revised the diagnostic 
and research criteria for AD in 2011, and this re-formulation of the diagnostic 
nosology were detailed in three publications that year [204, 205, 206].  According to 
the new NIA-AA criteria, a diagnosis of “pre-clinical AD” is based on the presence of 
relevant positive biomarkers (e.g., PET amyloid imaging) in conjunction with known 
risk factors for the disease (e.g., APOE e4 allele). The identification of individuals in 
this stage of prodromal AD is made essentially for research purposes only [204].  MCI 
due to AD includes patients with mild cognitive symptoms (impaired performance on 
measures of episodic memory function) with positive evidence of the disease from 
appropriate biomarker studies [205].  Ultimately, a diagnosis of AD is now based on 
criteria that account for recent developments in disease-specific biomarkers, which 
allow for confirmation of AD without the need to rely on post-mortem histopathology 
[206, 207,208]. 
Below, we briefly review the major overlapping pathophysiology between 
CVD, CBVD, and AD, all of which may be briefly summarized by Table 2.  
------------------------------------------------------------ 
Insert Table 2 About Here 
------------------------------------------------------------- 
 
Reduced Cerebral Blood Flow 
Normal brain function is dependent on receiving 20% of the cardiac output of 
oxygenated blood and both higher and lower blood pressure may reduce this cerebral 
blood flow [209]. Hence, impaired cardiac function may subsequently lead to both 
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reduced intracranial blood flow (e.g., as measured within the Circle of Willis) and 
ischemia, and this is readily observed in AD patients [210].  Reduced cerebrovascular 
reactivity was observed in a study of 18 young adult (mean age 24 years) carriers of at 
least one APOE ε4 allele [211].  Suri and colleagues surmise that this lifelong relative 
decrease in cerebral blood flow will lead to areas of hypo-perfusion and microvascular 
damage; thereby, contributing to aggregation of blood products, endothelial 
dysfunction and impaired Aβ clearance [211].  It is of note that the sample size in this 
study was small, and further investigation is required to elucidate the nature of the 
interaction between cerebral blood flow, APOE status, and AD.  A meta-analysis was 
conducted to investigate whether the changes in cerebral blood flow velocity and 
pulsatility index by Doppler ultrasonography in AD and VCID follow similar patterns. 
Both disease states were found to be associated with pronounced disturbances in 
cerebrovascular hemodynamics, with VCID patients showing significantly lower 
cerebral blood flow [212].  
Another factor that may contribute to reduced regional cerebral blood flow is the 
observed decrease of endothelial Nitric oxide (NO) synthesis in AD [213].  The 
enzyme eNOS is responsible for NO generation, which is important for cardiovascular 
homeostasis and acts as a vasodilator involved in the control of vasomotor function 
and local blood flow [214].  Endothelial production of NO is important for the 
prevention of CBVD, as it mediates protection from stroke by preserving cerebral 
blood flow and preventing inflammation, thrombosis and apoptosis [215]. Besides the 
CBVD contributions, it can also increase expression of APP and BACE1 consequently 
increase Aβ levels [216]. The evolving opinion is that cerebrovascular dysfunction is 
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not only present in CBVD, but also a prominent component of neurodegenerative 
pathologies such as AD [217]. 
 
Aβ deposition 
The amyloid cascade hypothesis postulates that neurodegeneration in AD is due to 
an abnormal accumulation of Aβ plaques in various areas of the brain [218], and the 
neurodegenerative processes in AD are the consequence of the imbalance between Aβ 
peptide production and clearance [219].  Recently, Yau and colleagues provided clear 
support for targeting Aβ clearance in early AD based on their longitudinal study of 16 
patients with an autosomal dominant mutation for early-onset AD. In their study, they 
demonstrated that amyloidosis is one of the earliest events in the neuropathology 
cascade leading to AD, with the majority of Aβ aggregation occurring before the 
progressive structural neurodegeneration and cognitive decline [220].   
The abnormal aggregation of Aβ protein in the brain neuropil may lead to either 
diffuse plaques and/or concentrated neuritic plaques, with the latter form of deposits 
often present in the vicinity of the cerebral microvasculature [221].  The Aβ protein, 
with its crystalline molecular structure, infiltrates the vessel walls and compromises 
the blood-brain barrier (BBB) [221].  Deposition of Aβ protein within the walls of 
cerebral blood vessels also leads to CAA, increasing the risk of cerebral hemorrhage 
[75], which is the most common clinical presentation of CAA [222]. In an APP/PS1 
transgenic mice study with induced hyperhomocysteinemia, Sudduth and colleagues 
showed that congophilic amyloid deposition was decreased in the parenchyma and 
significantly increased in the vasculature in CAA. This suggests that CBVD can 
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significantly impact Aβ distribution in the brain by vascular deposition, and that such 
deposition can induce microhemorrhages and activate neuroinflammation [223]. In an 
in vivo study of Sprague-Dawley rats, infusion of solubilized Aβ peptides enhanced 
constriction of cerebral and peripheral vessels, contributing to cerebral hypoperfusion 
and leading to decreased blood flow and increased vascular resistance [224].  The risk 
of both repeated hemorrhagic strokes, as well as ischemic events due to vessel wall 
stenosis and oligaemia, increases with continued Aβ accumulation for both CAA and 
AD patients. This pathologic cascade leads to medial temporal atrophy, cognitive 
decline and progressive brain atrophy [75].  Finally, vascular Aβ deposits observed in 
AD have been shown in vitro to induce degeneration of human and murine 
cerebrovascular smooth muscle and endothelial cells, resulting in vasoconstriction, 
intraluminal thickening, inhibiting angiogenesis, impairing vascular tone and 
decreasing total cerebral blood flow [225]. 
 
Morphological Changes in the Vasculature 
Arterial stiffness can be caused by structural or cellular change within vessel walls, 
and amyloid deposition in the vessels leads directly to this pathophysiological process 
[226]. The fragmentation of elastin alters the haemodynamics of vessel walls, resulting 
in increased systolic pressure by increasing the speed of the arterial wave that arrives 
prematurely during systole rather than during diastole [227].  Atherosclerosis also 
accelerates arterial stiffness [228], a frequent finding in patients with CVD.  Arterial 
stiffness is a clear risk factor for cognitive impairment in later life, as it can cause 
structural changes in the brain, such as white matter or cortical infarcts and cortical 
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brain atrophy [229, 230].  A recent systematic review of this association concludes 
that arterial stiffness is related to cerebral small vessel disease and decreased cognitive 
function [231].  
The deposition of Aβ in arterial vessel walls, and subsequent impediment of 
perivascular drainage of Aβ due to the AD pathology, can lead to intracerebral 
haemorrhage and an increase of Aβ peptides [75].  These morphological and 
architectural changes of the cerebral vasculature, studied in APP23 tg mice, start early 
in life. Along with the increase in observable amyloid plaques, there is also increased 
atrophy and altered blood flow, suggesting that disrupted microvasculature integrity 
can contribute to the progression of AD [232].  However, subtle changes in cerebral 
microcirculation are difficult to measure with high precision for the exploration of 
longitudinal changes within-subjects associated with increased disease burden. These 
subtle morphological changes may be more easily observed in the microvasculature of 
the retina.  Patients with AD have sparser retinal microvascular networks and other 
structural alterations that may mirror pathophysiological events found in the cerebral 
microvasculature [233].  Patients with AD show changes in retinal microvasculature, 
such as more tortuous retinal vessels and a narrowing of retinal venules [234]. These 
retinal vascular changes have been posited to precede the majority of 
neurodegeneration that characterizes AD progression [49].  
 
Alterations in Blood-Brain Barrier (BBB) Permeability 
The brain vasculature has cellular elements forming a developmental, structural 
and functional relationship with the brain tissue termed the neurovascular unit [226]. 
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The neurovascular unit has a fundamental role in the broad spectrum of pathologies 
underlying cognitive impairment. Neural activity requires a continuous and regulated 
blood flow in order to activate neurons, astrocytes and vascular cells through a wide 
variety of molecular signals (ions, arachidonic acid, metabolites, NO, adenosine, 
neurotransmitters, and neuropeptides) [235].  Specific neuroimaging techniques to 
visualize deleterious changes to the BBB are still under exploration. Several studies 
have shown that plasma proteins like prothrombin, which are typically excluded from 
the CNS, can be found within the microvessel walls and surrounding neuropil in AD 
patients, showing that the leakage of the BBB may be frequent in AD [236].  The 
vascular abnormalities found in the AD brain, such as alteration in smooth muscle 
cells and pericytes, endothelial cell thinning, loss of endothelial mitochondria and 
thickening of the vascular basement membrane, all contribute to alterations in BBB 
permeability [237]. The end result is a continuous cycle of reduced cerebral perfusion 
leading to acceleration of the neurodegenerative process, which further reduces 
perfusion. 
The changes in BBB permeability lead to an ionic imbalance and accumulation of 
toxic metabolic products. As a consequence, synaptic, neuronal and oligodendrital 
dysfunction occurs [238], since an intact BBB is crucial for limiting the entry of toxic 
products and cells into the brain. Glucose transport across the BBB is also impaired, 
and positron emission tomography (PET) studies show reduced regional metabolic 
rate in the AD brain [239].  Alterations on the (Na+/K+)-pump function of the BBB 
can result in fluid balance impairment, leading to deregulation of regional cerebral 
blood flow [240]. 
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Aβ accumulation can contribute to the leakage of the BBB [241].  These peptides 
spread across a defective BBB contribute to higher oxidative and nicrosative damage, 
as well as increased protease activity [75]. Aβ deposition leads to microglial 
activation, reactive astrocytosis and a multi-protein inflammatory response [242]. 
Studies of WT and APOE -/- mice show that BBB permeability increases with age and 
a defect in the BBB is exacerbated in APOE -/- mice [243,244].  Additionally, arterial 
stiffness results in an uncoupling of the neurovascular unit, and this disruption of the 
cerebral microenvironment is likely to contribute to brain dysfunction [245]. The 
resulting accumulation of Aβ in the neuropil and vessel walls leads to the activation of 
neuroinflammatory response, which plays an important role in BBB disruption [246].  
Anatomically, neuroinflammation may lead to transient increases in thickness of 
various cortical tissues, as well as at least one neuronal cell layer of the retina in 
preclinical stage disease. Snyder et al. (2016) have provided initial evidence to suggest 
an increase in the thickness of the retinal inner plexiform layer, in preclinical AD, and 
they postulate this volume increase may be partly due to a localized 
neuroinflammatory process and/or deposition of amyloid-containing inclusion bodies 
within the cell layer.  They suggest that this observation may precede a gradual 
thinning of neuronal cell layers (e.g., the ganglion cell layer) and the retinal nerve 
fiber layer with continued disease progression [247].   
 
Cholinergic neurodegeneration 
Postmortem studies have shown reduced activity of choline acetyltransferase, 
decreased numbers of nicotinic acetylcholine receptors, and reduced basal forebrain 
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cholinergic neurons (particularly in the nucleus basalis of Mynert), contribute to the 
oldest model of neurobiologic dysfunction in AD – the “cholinergic hypothesis” 
[248,249].  
This reduction in cholinergic innervation and activity may result, in part, from a 
reduction in noradrenaline release due to Locus coeruleus (LC) neuron loss [250]. 
There is a strong reciprocal connection between the LC and the prefrontal cortex, and 
this area is involved in the mediation of executive functioning, memory and vigilance 
[251]. The LC is responsible for exerting an excitatory influence on wakefulness-
promoting nuclei, such as the cholinergic nuclei of the septal area, medial preoptic 
area and substantia innominata [252]. Pathological changes in the LC occur early in 
AD [253], and this reduction in LC activity likely leads to the common finding of 
reduced levels of arousal and alertness in AD patients. The number of LC neurons 
projecting to areas such as the hippocampus and the frontal cortex, decline slowly with 
normal aging, and this may result in some modest age-related changes in spatial 
learning and memory [254]. 
This structural and functional loss in the LC affects both efferent and afferent 
pathways. The LC exerts both direct (via a descending excitatory noradrenergic 
pathway) and indirect effects (via modulation of the activity of other premotor 
sympathetic nuclei) on preganglionic sympathetic neurons in the intermediolateral cell 
collumn [255]. The LC sends efferent inputs to the nucleus tratus solitarius, which is 
critical for the modulation of the vasomotor response to changes in blood pressure 
through vagal nerve stimulation and autonomic inputs to the heart.  The vagal nerve 
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provides cholinergic input to increase parasympathetic activity, which decreases heart 
rate and lowers blood pressure when needed [256]. 
The earliest stages of AD are marked, in part, by altered function of the basal 
forebrain cholinergic system, with eventual degenerative changes including neuronal 
loss [257,258]. We have recently reported that a down-regulation of central 
cholinergic neurotransmission appears to be one of the earliest neuropathological 
changes in preclinical AD [259], and we have also found that individuals with 
evidence of both decreased central cholinergic tone and amyloid aggregation within 
the anterior cingulate region show evidence of increased resting cardiac workload at 
rest [52]. The aggregation of Aβ plaques in the neocortex, within this specific region 
of interest that is part of the central cholinergic system, appears to be directly 
associated with increasing cognitive impairment as well as the higher myocardial 
oxygen consumption at resting state [52].  In fact, there is a growing body of literature 
to suggest a direct link between Aβ aggregation, basal forebrain cholinergic damage, 
and diminished cholinergic innervation of cortical blood vessels, leading to the 
microvascular pathology that has been documented in the majority of AD cases 
[260,261,262,263].We are currently exploring whether indices of phasic vagal cardiac 
control, such as resting sinus arrhythmia (RSA) and heart rate variability (HRV) are 
also related to cortical amyloidosis in preclinical AD, since both RSA and HRV are 
directly modulated by muscarinic cholinergic and nicotinic autonomic 
neurotransmission.  
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General Discussion  
 
This review is intended to tie together several lines of research on the shared 
mechanistic relationships between AD, CVD, and CBVD.  The literature that binds 
these diseases is both large and confusing.  Why is AD so tightly connected to 
disruption of the cerebrovasculature and to cardiologic disease?  Why do these broad 
disease entities share so many risk factors and mechanistic relationships?  One 
compelling answer to these larger questions may come from the field of medical 
anthropology and attempts to study the global distribution of APOE gene alleles across 
the human species. The ε4 allele is the ancestral form of APOE [264,265] and is 
associated with both higher absorption of cholesterol at the intestinal level and higher 
plasma cholesterol levels in carriers. The phenotypic expression of this allele would 
likely confer a survival benefit to humans that evolved with limited food supplies and 
in harsh weather conditions.  Expression of the Ɛ4 allele under contemporary/modern 
diet, exercise and environmental conditions, together with the relatively recent and 
dramatic increase in human longevity may have now led to the identification of the Ɛ4 
allele as pleiotropic, showing susceptibilities for both CVD and AD [265].  Although 
this anthropological viewpoint is not universally accepted, nor the focus of the current 
review, it affords us an over-arching heuristic model to explain the strong relationship 
between CVD, CBVD and AD. 
Another question that arises from the frequent co-incidence of AD, CVD, and 
CBVD is whether or not they are the end result of shared etiologic mechanisms. If one 
supposes a direct, bi-directional causal link between these disease clusters, then all 
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cases of CVD and/or CBVD would also demonstrate AD pathology, and we know this 
not the case. Rather, we have reviewed a large literature indicating that 
vascular/cerebrovascular pathology is present for most individuals with AD but not all 
of them.  In support of this notion, an autopsy study with the largest cohort to date (N 
= 5,715) showed increased prevalence of CBVD and vascular pathology in AD 
compared to healthy controls and patients with dementias of non-AD etiologies [266]. 
So what, then, is the causal nature of the relationships between these diseases?  
To answer this question, it is important to determine whether the cognitive effects of 
AD and CVD/CBVD are additive or synergistic. This is a topic that continues to elicit 
considerable scientific exploration. It is possible that AD and CVD/CBVD contribute 
independently to dementia, such that the severity of the dementia is a cumulative 
result of two separate pathologies [196]. Alternatively, these disease processes could 
be synergistic, such that the pathology of one accelerates the progress of the other.  
The majority of the literature reviewed herein supports the model of a synergistic 
interaction between vascular/cerebrovascular and neurodegenerative processes early in 
disease pathogenesis. This theory is further supported by a reciprocal relationship 
between Aβ accumulation and cerebrovascular insult such that Aβ deposition 
provokes vascular/cerebrovascular changes [75] and vice versa [267,268].  Clinical 
studies demonstrate that even mild cerebrovascular pathology results in reduced 
cognitive performance in very early AD [78, 269].  It is possible that both additive and 
synergistic processes are affecting cognitive decline at different stages of these disease 
processes. This theory is congruous with variability in observational findings based on 
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timing, severity, and duration of CVD risk factors.  In fact, it has been suggested that 
later disease stages of disease could demonstrate a more additive relationship [270]. 
There is evidence that vascular/cerebrovascular pathology can accelerate the 
progression of preclinical AD and speed disease evolution [271,272]. The 
relationships between AD and CVD/CBVD are complex, and further investigation is 
required in order to discern the exact nature of these relationships at different stages of 
disease progression. We suggest that, because AD is so frequently accompanied by 
comorbid vascular and/or cerebrovascular symptoms, it is both clinically and 
scientifically relevant to consider these pathologies concurrently, regardless of 
whether their respective underlying pathologic mechanisms are independent and 
additive, or functionally related and synergistic. 
We support the widely studied hypothesis that effectively controlling vascular risk 
factors serves to delay onset of AD. In fact, a recent statement by the World Dementia 
Council suggested that “Regular physical activity and management of cardiovascular 
risk factors (e.g. diabetes, obesity, smoking, and hypertension) are associated with a 
reduced risk of cognitive decline and may reduce the risk of dementia” [273,274]. A 
recent cross-sectional study concluded that the use of certain medications to treat 
vascular disease, especially angiotensin receptor blockers and diuretics, may decrease 
Aβ accumulation [275].  In a recent review, Deckers et al (2015) [276] found that the 
most common modifiable risk factors for AD development included hypertension, 
diabetes, midlife obesity, physical inactivity, hyperlipidemia, and smoking.  Simple, 
inexpensive interventions involving diet and exercise in midlife could be very useful 
tools to prevent CVD, CBVD, and AD. These interventions are currently under 
 36 
 
evaluation by several large prospective clinical trials, including the CAIDE [277] and 
the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and 
Disability (FINGER – [278]). Nonetheless, preliminary results indicate that the 
complex multifactorial nature of AD requires interventions that simultaneously target 
multiple risk factors and disease mechanisms during the preclinical stage of the 
disease [277,278].The CAIDE screening tool has been developed based on vascular 
and metabolic factors shown to increase dementia risk in order to identify individuals 
who are at-risk for dementia and who require preventive intervention [45] and this has 
recently been developed into a freely-available smartphone application [277]. 
 The validation of sensitive and reliable measures of dementia risk that account for 
CVD susceptibility (e.g., CAIDE), paired with lifestyle intervention techniques to 
control or reduce these same risk markers, will ultimately lead to a better 
understanding of the relationship between these two disease clusters.  The exploration 
of the dynamic pathogenic relationships between AD and CVD/CBVD has the 
potential to lead to a reduction and/or delay in AD incidence. In accordance with 
earlier work revealing that interactions between mechanistic, genetic, and lifestyle 
factors influence vascular disease, we expect that these multifactorial interventions 
targeting common mechanistic and lifestyle factors in AD and CVD/CBVD will 
confirm that the adoption of a heart-healthy lifestyle has the potential to contribute to a 
future decline in all three disease processes.  
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Future Directions 
Despite the rapid advancement of medical technology, we are still developing 
a suite of reliable and sensitive diagnostic markers to identify individuals at risk for 
AD prior to onset of clinical symptoms. This is an area of research that needs to be 
urgently addressed in order to enable the study of early interventions to maintain 
quality of life in premorbid AD and to reduce the individual and societal burden of the 
disease. There are currently several secondary prevention trials aimed at 
pharmacologically slowing or reducing the Aβ accumulation that occurs in preclinical 
AD, but as of this writing these secondary prevention trials are still in progress and we 
do not yet have successful therapies to prevent or slow/reduce disease progression.  It 
is typically the case that such large prospective studies seek to exclude participants 
with significant cardiovascular or cerebrovascular comorbidities. Given the evidence 
supporting a substantial overlap of epidemiology, genetics, risk factors, and 
mechanistic factors in vascular and AD pathology, we argue that future secondary 
prevention trials should focus on a more heterogeneous and phenotypically 
representative population.  
Aside from clinical trials and recruitment science, there continues to be an 
outpouring of literature aimed at untangling the mechanistic relationships between 
CVD, CBVD, and AD. Recently, the National Institutes of Health (NIH) launched the 
Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease (M2OVE-
AD) Consortium, the primary aim of which is to construct a comprehensive model of 
Alzheimer’s disease that more accurately reflects its complex underpinnings, and the 
multiple pathways of disease development. The main objectives of this initiative are to 
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elucidate the complex mechanisms by which cardiovascular risk factors influence the 
development and progression of AD, and to identify new targets for treatment and 
prevention. Thus far, the consortium supports five project areas addressing a wide 
range of topics, including: the contribution of Alzheimer’s risk genes (APOE E4) to 
AD and CVD, the contribution of DM to AD, CVD, and CBVD, the contribution of 
hypertension to AD development and progression, identifying metabolic signatures 
underlying risk factors for both AD and CVD, and investigating the mechanism of Aβ 
accumulation and clearance at the molecular, single-blood vessel, and whole brain 
level and the relationship of Aβ accumulation at all three levels in AD and CBVD.  
Moving forward, studies such as these that investigate the interaction of vascular 
biology with genetic, cardiometabolic, and lifestyle risk factors and AD pathology will 
be crucial to the development of therapeutic agents.  
There are many questions about the relationships between AD, CBVD, and 
CVD that remain unanswered.  One important public health question is how these 
diseases intersect in the oldest old. The World Health Organization has reported a 
world-wide dementia incidence of 47.5 million in 2015, and a projected incidence of 
75.6 million in 2030. The largest risk factor for AD, CVD, and CBVD is increasing 
age. In the United States, the population of adults aged ≥90 is expected to grow over 
six-fold by 2050 [271]. As the average lifespan increases, the social and economic 
consequences of AD, CVD, and CBVD are expected to expand accordingly. Due to 
difficulties in finding, recruiting, and diagnosing the oldest-old, very little literature 
exists examining the relationships between AD, CBVD, and CVD in this population. 
Future population-based studies should aim to include this cohort in order to further 
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understand the nature of disease interactions over time, and to identify prevention 
targets to reduce cardiovascular risk (i.e. blood pressure, glycemic index, and 
cholesterol levels) in these specific populations. More accurate models are required for 
assessing prognosis and life expectancy in older adults with AD, CVD, and/or CBVD 
in the context of multiple chronic conditions.  
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Tables 
 
Table 1.  Shared evidence-based treatments for cardiovascular disease (CVD) and 
Alzheimer’s disease (AD).  Note: Given the breadth of this literature, all cited 
references are exemplars published within the past 10 years, and all are empirical 
reports. 
Specific Medication 
Interventions 
Clinical Effects in Treatment of 
CVD 
Clinical Effects in Treatment of AD 
Diuretics Thiazide diuretics lead to 
lowering of blood pressure 
[279,280]. 
Long-term use of diuretics may be 
associated with decreased 
incidence of AD [61,62]. 
Angiotensin receptor -
1blocker (ARB) or 
angiotensin-converting 
enzyme (ACE) 
inhibitor 
Reduce risk of cardiovascular 
events [281,282]. 
ARB and ACE inhibitors may 
slow progression of symptoms in 
mild-moderate AD [62,64]. 
β-blockers β-blockers can prevent 
cardiovascular events in patients 
at increased cardiovascular risk 
[283,284]. 
β-blocker use is associated with a 
lowered risk of developing 
cognitive impairment in older 
adults without dementia [63,65]. 
Statins Reduce risk of cardiovascular 
events [285,286]. 
Mixed literature, with no 
consistent evidence that statins 
reduce the incidence of AD or 
slow cognitive decline [87,88]. 
Anti-Inflammatory 
Drugs  
Mixed literature on use of Non-
aspirin anti-Inflammatory drugs 
to reduce cardiovascular risk 
[287,288].  Low-dose aspirin is 
commonly used as an anti-
platelet agent for secondary 
CVD prevention. 
Mixed literature, suggesting that 
NSAIDs may confer modest 
protective effects [10,11]. Low-
dose aspirin is commonly used as 
an anti-platelet agent for stroke 
prevention. 
Insulin Treatment Effective diabetes treatment 
confers long-term beneficial 
effects on risk of CVD 
[289,290]. 
Intranasal insulin appears to 
improve cognition and modulates 
Aβ aggregation in early AD [111, 
94]. 
 
Specific Behavioral 
Interventions 
  
Aerobic Exercise & 
Physical Fitness 
Long-term protective effects on 
risk of cardiovascular disorders 
[291,292].  
Aerobic exercise promotes brain 
vascularization and may reduce 
vascular risk factors as well as to 
improve cognitive function 
[125,127]. 
Healthy Diets (e.g., 
MIND diet) 
Healthy diets may protect 
against CVD [293,294]. 
High-fat diets have shown an 
increased risk for AD  
[112,115]. Conversely, carefully 
designed diets have been shown to 
confer protective effects [113,114].  
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Table 2.  Domains of shared patient characteristics and pathophysiology between 
cardio- and cerebrovascular disease, and Alzheimer’s disease. 
 
 
Patient Characteristics AD CVD/CBVD Key References numbers 
Age range Yes Yes 2, 34,35,189 
Genetic risk factor Yes Yes 23-33, 264-266 
Hypertension/ Hypotension Yes Yes 34,35,38,39-44,51-69 
High Cholesterol Yes Yes 36,71-86 
Diabetes Mellitus Yes Yes 34,35,38-44,89-110 
Obesity Yes Yes 111-121 
Poor physical fitness Yes Yes 124-137 
Smoking Yes Yes 34,35,39-45,143-154 
History of depression Yes Yes 157-168 
Pathogens (e.g., fungal) Yes Yes 169,170 
Air pollution Yes Yes 176-179 
    
Pathophysiology AD CVD/CBVD Key References numbers 
Reduced cerebral blood flow Yes Yes 182,209-217 
Aβ deposition Yes No 184,218-225 
Morphological changes in vasculature Yes Yes 49,180,181,226-234 
Alterations in BBB permeability Yes Yes 235-247 
Cholinergic neurodegeneration Yes Yes 248-263 
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Abstract 
 
 
To explore early autonomic cardiac changes in pre-clinical AD, we have evaluated 
electrocardiologic measures of vagal tone for 63 adults (ages 55-75) at rest, during 
cognitive testing, and then again at rest. All subjects had multiple risk factors for AD, 
and all completed amyloid PET scans (18F-Florbetapir) to determine amyloid 
positivity (Aβ+). 
No change in ECG measures were observed for Aβ+ participants under each testing 
condition, whereas Aβ- subjects showed an expected increase in vagal tone during the 
cognitive stress condition.  These findings suggest an early relationship between 
cortical Aβ accumulation, a precursor to AD development, and autonomic cardiac 
function. 
 
 
Keywords 
Alzheimer’s disease, cardiac, vagal tone, resting sinus arrhythmia, aging, heart rate 
variability 
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Introduction 
 
 
A recent review of the complex relationship between Alzheimer’s disease 
(AD), cardiovascular disease (CVD), and cerebrovascular disease (CBVD) [1] 
highlights the many shared risk factors and pathophysiologic mechanisms across these 
diseases and, as a result, the preclinical stages of these diseases may often 
concurrently affect the same at-risk population [1]. Clinical studies demonstrate that 
even mild cerebrovascular pathology results in reduced cognitive performance in very 
early AD [2,3].  Additionally, there is evidence that vascular/cerebrovascular 
pathology can accelerate the progression of AD [4,5]. Moreover, the blood-brain 
barrier seems to be disrupted early in AD, causing dysfunction in brain perfusion [6] 
and reduced cerebral blood flow [7]. It remains unclear just how early in the disease 
course the shared pathological relationships between AD, CVD, and CBVD can be 
observed.  The exploration of the mechanistic relationships between these disease 
clusters in a preclinical population is important to better understand the complicated 
co-occurrence of these three diseases. 
We recently examined the relationship between CNS amyloid beta (Aβ) 
burden, and a simple measure of myocardial oxygen consumption: rate pressure 
product (RPP), a well-known cardiac workload marker that reflects myocardial stress 
based on the number of times that the heart needs to beat per minute in relation to the 
arterial blood pressure that it is pumping against. In cognitively normal participants at 
high-risk for the development of AD [8]. This work supports a relationship between 
elevated neocortical Aβ aggregation and inefficient myocardial oxygen consumption 
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in the absence of significant metabolic demands (after accounting for expected effects 
of age).  
In the current study, we sought to explore if the changes in cardiac workload 
that we see in preclinical AD during cognitive testing are due to centrally-mediated 
changes in vagal tone measured by vagal ratio and the resting sinus arrhythmia (RSA).  
Both of these indices become less reactive and they decrease in amplitude with normal 
aging, due to declines in parasympathetic tone [9,10].  The vagal ratio is the ratio 
between low and high frequency components of the Heart Rate Variability (HRV) and 
the RSA is a measure of the HRV in synchrony with respiration.  In this study, rapid 
changes in these two indices of vagal tone were measured before, during, and 
immediately after the administration of a cognitive stressor, to explore the adaptive 
flexibility of parasympathetic autonomic function in response to a mild cognitive 
stressor (performance on a hidden maze learning task).  
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Methods 
 
Participants: Sixty-three adults aged between 55 and 75 years (mean age = 
62.79 years), all at some risk for development of Alzheimer’s disease (AD) based on 
the presence of two risk factors for the disease (a first degree family history and 
subjective memory complaints), were recruited for a longitudinal study of individuals 
with possible preclinical AD [11].  From this larger sample, we identified 15 
participants who were categorized as presenting with preclinical stage disease based 
on evidence of both 1) elevated neocortical beta-amyloid burden as determined by 
PET amyloid imaging [12,13]; and 2) relative cognitive impairments in response to a 
challenge with a very low-dose muscarinic anticholinergics [11,14].  Potential 
participants were excluded from this study if they presented with diagnoses of either 
mild cognitive impairment (MCI) or AD, following NIA-AA diagnostic criteria 
[13,15], diabetes, or histories of any neurological or psychiatric disorders.  With 
respect to cardiovascular risk, four of 15 subjects in the preclinical AD group (26.7%) 
and 12 of 48 subjects in the control group (25%) presented with hypercholesterolemia 
that was under medication control. Two individuals in the preclinical AD group 
(13.3%) and 8 persons in the control group (16.6%) were under treatment for 
hypertension. For all subjects, a score on the Mini Mental State Examination (MMSE) 
>27 was required for study entry.  
With respect to genetic risk for AD, eight of 15 individuals (53%) in the 
preclinical AD group (Florbetapir PET SUVr scores ≥1.10) had at least one copy of 
the APOE ε4 allele, whereas 20 of 45 individuals (45%) in the control group 
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(Florbetapir PET SUVr scores < 1.10) had at least one copy of the APOE ε4 allele. 
Hence, roughly half of the subjects in each group presented with this additional risk 
factor for AD, but due to small sample sizes we were not able to further evaluate the 
specific effect of APOE genetic risk on the relationship between vagal tone and 
cognitive performance. Subject demographic information, for both groups, are 
provided in Table 1. 
 
Neuroimaging: PET scans were performed at baseline, with 370MBq (10 mCi 
+/- 10%) bolus injection of 18F-florbetapir administered intravenously.  PET 
standardized uptake value (SUV) data were summed and normalized to the whole 
cerebellum SUV, resulting in a region-to-cerebellum ratio termed SUV ratio (SUVr). 
We defined amyloid positivity (Aβ+) as individuals with elevated ligand binding 
(SUVr≥1.1) in the anterior cingulate (ACC).  Consistent with Lim et al. (2015) [14], 
this specific region of interest was selected because: (1) the young age of participants 
enrolled in the study [16,17], and as such, we would not expect widespread neocortical 
amyloidosis in this very early preclinical disease stage, (2) the relationship between 
the ACC and early changes in cholinergic tone [18,19], and (3) emerging research that 
suggests that increased Aβ burden, in the ACC specifically, is related to memory 
changes in early AD [20,21].  The SUVr calculation was performed using MIMneuro 
software [22].  For all cases, Aβ positivity was confirmed by consensus over-read by 
two board-certified radiologists who were also board-certified in Nuclear Medicine 
[14]. 
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Cardiac measures: Electrocardiographic (ECG) measures of resting-sinus 
arrhythmia (RSA) and vagal ratio (described above) were recorded by BioPac Systems 
[23] for each participant: 1) at rest, sitting quietly in a semi-supine position (120 
seconds); 2) during the performance of the Groton Maze Learning Test (GMLT; 
approx. 190 seconds); and 3) post-test at rest in a semi-supine position (120 seconds). 
Both measures were calculated using the Heart Rate Variability (HRV) 
analysis of fixed- width intervals around events, which follows the European Heart 
Journal guidelines [24] for the spectral method with the Multi-epoch HRV processing 
[25].  
 RSA is computed using the peak-valley method, which uses both a recorded 
ECG signal and a respiration signal. By using respiration information, this analysis 
method can provide breath-to-breath analysis that does not require parameter tweaking 
for individual subjects [23,26]. 
The vagal ratio measure accounts for the fact that parasympathetic control via 
the vagus nerve is believed to primarily modulate the R-R intervals at a rate of 
between 0.15 and 0.4 cycles per second. Frequency based analysis of HRV in 
AcqKnowledge computes vagal ratio as the amount of power in the parasympathetic 
band normalized to an approximation of the total power in the signal [25].  
Cognitive Assessment:  All participants completed the Groton Maze Learning 
Test (GMLT; http://www.cogstate.com) as a mild cognitive stressor, during the ECG 
recording.  The GMLT is a computerized hidden spatial maze learning task, developed 
by one of the authors (P.J.S.) as a measure of working memory, learning efficiency 
and reasoning/problem solving [27].  This GMLT composite score was used to explore 
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group differences in performance.  All subjects completed a practice trial of the 
GMLT, to allow for initial task familiarity; and after a 10-min break, all subjects 
repeated the GMLT as a baseline assessment (at which time ECG recordings were 
obtained, as described above). 
Additionally, all subjects completed a test of verbal episodic memory: 
International Shopping List Test (ISLT) [28], the Mini-Mental State Examination 
(MMSE) as a measure of general cognitive function, the 15-item Geriatric Depression 
Scale and the Depression, Anxiety and Stress Scale (DASS).  Subjective memory 
impairment was determined using the Memory Complaint Questionnaire (MAC-Q). 
All measures were performed by trained staff supervised by a licensed clinical 
neuropsychologist. 
 
Statistical Treatment of Data: Generalized estimating equations (GEEs) were 
used to compare within-subject changes in vagal ratio and RSA across the three time 
points (rest à cognitive task à rest) between preclinical AD subjects (N=15) and the 
control subjects (N=48). GEEs are generalized linear models wherein the within-
subjects (or other) nesting is accounted for in the residual error of the model (R-side), 
as contrasted with constructing random effects separate from the residual (G-side as in 
random, mixed, or hierarchical models) [29]. In our case, a compound symmetry 
variance-covariance matrix was used across testing phases, which assumes a common 
variance for each phase as well as a common covariance between all phases. Despite 
best intentions and approach, there can be non-obvious imprecision in these 
specification and so classical sandwich estimation [30] was used to adjust for any 
misspecification in this structure by subsequently adjusting the variances and 
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covariances in the structure based on the actual distribution of the data (inverse of the 
empirical variance “sandwiched” between model variance(s)). The Shaffer step-down 
adjustment was used to maintain alpha at 0.05 across all comparisons within each 
model.  Figures 2 and 3 were designed to simultaneously illustrate between- and 
within-participant variation. 
This study was approved by and complied with the regulations of Rhode Island 
Hospital’s Institutional Review Board, and all participants provided written informed 
consent. 
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Results 
 
There were no statistically significant differences between the two groups for 
any demographic or clinical outcome, with the exception of the expected elevation in 
cortical amyloid aggregation as demonstrated on florbetapir PET scan (Table 1).   
There were also no between-groups differences in at-rest vagal ratio or RSA, with 
respect to main effects for APOE ε4 carrier status, presence of hypercholesterolemia 
and hypertension (p > .05 for all analyses). 
----------------------------------------------------- 
Insert Table 1 About Here 
----------------------------------------------------- 
 
With respect to performance on the GMLT, no between-groups differences on 
the composite score [14], were found between those with Aβ+ PET scans vs. those in 
the Aβ- healthy control group. 
----------------------------------------------------- 
Insert Figure 1 About Here 
----------------------------------------------------- 
 
 
However, subjects in the healthy control group (those with Aβ- PET scans) 
showed an increase in vagal ratio during the cognitive task condition, relative to either 
of the two at-rest conditions (Pre-GMLT: p=0.0061; adj. p=0.0304; Post-GMLT: 
p<.0001; adj. p=0.0007), with post-GMLT vagal ratio not differing significantly from 
pre-GMLT levels (p=0.2283; adj. p=0.9185).  In contrast, the preclinical AD (Aβ+) 
group did not consistently show any change in vagal ratio at any point during testing 
(pre- vs. GMLT p=0.1837, GMLT vs. post- p=0.2221, post- vs. pre-GMLT p=0.7883; 
adj. p =0.9985 for all).  Further, the increased vagal ratio during the cognitive stress 
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condition (p=0.0099; adj. p=0.0304) and subsequent decreases (p=0.0013; adj. 
p=0.0007) for the Aβ- group differed significantly from the Aβ+ group. 
----------------------------------------------------- 
Insert Figure 2 About Here 
----------------------------------------------------- 
 
Similarly, to vagal ratio, the Aβ- subjects showed a significant increase in RSA 
during the cognitive task condition, relative to either of the two at-rest conditions (Pre-
GMLT: p<.0001; adj. p<.0001; Post-GMLT: p=<.0001; adj. p=0.0003), with post-
GMLT RSA not differing significantly from pre-GMLT levels (p=0.2471; adj. p=1.0).  
As with the vagal ratio measure, those in the Aβ+ group did not consistently show any 
change in RSA at any point during testing (pre- vs. GMLT p=0.6321, GMLT vs. post- 
p=0.7719, post- vs. pre-GMLT p=0.8510; adj. p =1.0 for all). Further, the increased 
RSA scores during the cognitive stress condition (p=0.0021; adj. p=0.0104) were 
significantly larger for the Aβ- group compared to the Aβ+ group. The subsequent 
decrease in RSA for the Aβ+ group after the cognitive stress were significantly greater 
than for the Aβ- group prior to adjustment, but not after multiplicity adjustment 
(p=0.0304; adj. p=0.0913). 
----------------------------------------------------- 
Insert Figure 3 About Here 
----------------------------------------------------- 
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Discussion 
 
Participants in this preclinical AD (Aβ+) group demonstrated statistically 
significant attenuation in the reactivity of two separate measures (vagal ratio and 
RSA) of parasympathetic response to a mild cognitive stress condition.  Not only was 
the magnitude of their response to the cognitive stressor less than those without 
elevated neocortical Aβ, but no significant differences found for these measures, 
within the Aβ+ group, across any of the three ECG time points. In order to further 
explore the relationship between neocortical Aβ aggregation and inefficient 
myocardial oxygen consumption in the absence of significant metabolic demands [8], 
it is essential to rely on metrics that accurately reflect the autonomic processes that 
control cardiac function.  Cardiac autonomic dysfunction is prevalent among 
individuals with AD, and this generally reflects a decrease in parasympathetic activity 
[31,32]. It has been previously shown that individuals with MCI demonstrate 
significant parasympathetic deficits [33]. The parasympathetic nervous system (PNS) 
influences heart rate by the release of acetylcholine (ACh) via the vagus nerve, which 
causes the heart rate activity to slowdown. This reduction in PNS activity is often 
referred to as vagal withdrawal, and is indicative of impaired autonomic function [34].   
The ratio between low and high frequency components of the HRV (the LF/HF 
ratio, or vagal ratio) has long been relied on as a measure of sympatho-vagal balance 
[35,36,37].  Healthy individuals under mental stress while completing a cognitive task 
showed a reduced HF HRV component compared to a control group who were 
monitored whilst awake and at rest [38,39].  The clinical reliability of this vagal ratio 
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as marker of autonomic activity has been nonetheless controversial [40,41]. Therefore, 
we have chosen to supplement this measure of autonomic cardiac function in 
preclinical AD by computing the respiratory sinus arrhythmia (RSA), which considers 
the variation in heart rate during the breathing cycle and is commonly relied on as a 
measure of parasympathetic nervous system activity. Typically, both vagal ratio and 
RSA decrease with normal aging due to decline in parasympathetic tone [9,10]. 
Disruption of cholinergic neurotransmission with low-dose scopolamine has 
been previously shown to exacerbate subtle cognitive deficits that are otherwise not 
(yet) detectable for subjects in the Aβ+ group [14], whereas standard baseline testing 
with the GMLT does not reveal any group differences.  We believe that the subjects 
enrolled in the Aβ+ group, for this study, are in the preclinical stage of the disease and 
that it might be too early to observe clear impairments in learning efficiency and 
working memory/executive function unless such defects are unmasked by 
intentionally down-regulating cholinergic tone [14]. 
Participants in this Aβ+ group, however, did not consistently show changes in 
vagal ratio or RSA at any point during the experiment, failing to demonstrate the 
expected response to modest stress elicited during cognitive task performance.  Both 
measures were expected to show modest increases, reflecting heightened autonomic 
arousal, during completion of a neuropsychological test, even after adjusting for age 
effects [42]. Enhanced vagal ratio is characterized by greater vagal reactivity and 
faster vagal recovery from psychological stressors, and it has been linked with greater 
ANS flexibility and an improved response selection in the face of stress [43,44] and 
return to homeostasis [45]. Conversely, in a study of healthy male sailors who 
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completed a fitness training program, those with higher vagal ratio scores 
demonstrated improved performance on measures of working memory, reaction time 
and attentional controls [46].  In our study, the Aβ- group demonstrated an expected 
increase in vagal ratio in response to the cognitive stressor, whereas the Aβ+ group 
demonstrated no change in vagal ratio across all three testing conditions. 
The same pattern of results was observed for the related RSA measure, with 
participants in the Aβ- group showing an expected increase in RSA during GMLT 
performance.  RSA is a composite of integrated respiratory and cardiovascular 
responses [47] that are responsive not only to metabolic demands but also to levels of 
alertness and, in humans at least, different types of emotion, mental activity and 
arousal metabolism [48]. Typically, expression of RSA decreases with age [49]; 
however, adults in excellent cardiovascular health, such as athletes, are likely to have 
a higher RSA [50].  Higher RSA is also usually associated with fewer errors in a 
complex memory task, on measures of attentional control and response selection and 
on cognitive function tasks that are associated with the integrity of the ACC [51].  
Aβ+ participants showed decreased RSA compared to Aβ- during the cognitive test, 
and this pattern was present in participants with cognition impairments or with 
diabetes and cardiovascular disease [10]. 
Cardiac autonomic dysfunction is prevalent among individuals with AD, as 
reflected by exacerbated sympathetic nervous activity and decreased parasympathetic 
nervous activity [31,52,53,54].  The results of the current study suggest that for 
individuals identified as falling within the preclinical stage of AD (our Aβ+ group), 
there is a muted response on two related indices of phasic vagal cardiac control, RSA 
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and vagal ratio, when presented with a modest cognitive stressor. Both RSA and vagal 
ratio are directly modulated by both muscarinic and nicotinic cholinergic autonomic 
neurotransmission, and the earliest stages of AD are marked, in part, by altered 
function of the basal forebrain cholinergic system, with eventual degenerative changes 
including neuronal loss [54]. We have recently reported that a down-regulation of 
central cholinergic neurotransmission appears to be one of the earliest 
neuropathological changes in preclinical AD [14] and we have also found that 
individuals with evidence of both decreased central cholinergic tone and amyloid 
aggregation within the ACC region show evidence of increased resting cardiac 
workload [8]. The aggregation of Aβ plaques in the neocortex, within this specific 
region of interest that is part of the central cholinergic system, appears to be directly 
associated with higher cognitive impairment as well as myocardial oxygen 
consumption [8].  These results add to a growing body of literature that suggests a 
direct link between Aβ aggregation, basal forebrain cholinergic damage, and impaired 
cardiovascular function, even in the preclinical stage of Alzheimer’s disease [1]. 
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Tables 
Table 1. Demographic Characteristics 
 
 Main Outcome Full sample 
(n = 63) 
Preclinical 
AD 
(n = 15) 
Healthy 
Controls  
(n = 48) 
  
  N (%) N (%) N (%) p  
Sex No. of female 39 (61.9%) 11 (73.3%) 28 (58.3%) .296  
APOE Number of Ɛ4 
carriers  
29 (46%)          8 (53.3%)             21(43.8%) .516  
Hypertension                                       Number of
participants 
10 (15.9%) 2 (13.3%) 8 (16.6%) .758  
Hypercholesterolemia Number of 
participants 
16 (25.4%) 4 (26.7%) 12 (25%) .897 
 
  Mean (SD) Mean (SD) Mean (SD) p Cohen’s d  
Age No. of years 62.79 (5.35) 63.93 
(6.31) 
62.44 (5.04) .349 0.28 
Education No. of years 17.21 (2.77) 17.47 
(3.46) 
17.14 (2.55) .689 0.12 
Florbetapir PET 
SUVr (ACC region 
of interest) 
Standardized 
Uptake Value 
ratio 
1.04 (0.19) 1.30 (0.20) 0.95 (0.08) .000 2.95 
GDS Total Score 1.86 (2.16) 1.60 (1.45) 1.94 (2.35) .602 -0.16 
DASS Depression 
Subscale 
Total 
Depression 
Subscale Score 
3.56 (6.70) 2.60 (2.59) 3.87 (7.56) .526 -0.19 
DASS Anxiety 
Subscale 
Total Anxiety 
Subscale Score 
2.73 (4.53) 2.40 (3.58) 2.83 (4.83) .752 -0.09 
DASS Stress 
Subscale 
Total Stress 
Subscale Score 
6.73 (6.77) 6.67 (4.55) 6.74 (7.38) .969 -0.01 
Body Mass Index Body Mass 
Index 
26.69 (5.50) 28.66 
(7.95) 
26.07 (4.41) .113 0.48 
MMSE Total Score 29.05 (1.02) 28.93 
(1.16) 
29.08 (0.99) .624 -0.15 
ISLT Total Recall Total words 
recalled 
25.59 (4.22) 24.73 
(4.46) 
25.85 (4.16) .374 -0.26 
                                     
*Note: SUVr = standardized uptake value ratio; ACC = Anterior Cingulate Cortex; GDS = 
Geriatric Depression Scale; DASS = Depression, Anxiety, and Stress Scale; MMSE = Mini 
Mental State Examination; ISLT = International Shopping List Test; bolded value is 
significant at the p<.001 level
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Figures Legends 
 
Figure 1. GMTL composite z-scores for participants with low (left) versus high 
(right) for Aβ aggregation in the anterior cingulate region of interest (PET amyloid 
imaging) (p > 0.05).  
 
Figure 2. Plots of vagal ratio in patients testing negative (blue, left) and positive 
(red, right) for Aβ (ACC) as a function of pre-, during, and post-GMLT testing. 
Least squares means (large circles) and 95% confidence intervals were adjusted for 
age. Small circles indicate the raw individual patient values for each phase of 
testing in order to convey the variability in values between patients. Light gray 
lines illustrate the individual changes relative to pre-GMLT testing (normalized to 
pre-GMLT by subtraction) in order to convey the consistency of within-subject 
changes. Aβ-  group showed an increase in vagal ratio during the cognitive task 
condition, relative to either of the two at-rest conditions (Pre-GMLT: p=0.0061; 
adj. p=0.0304; Post-GMLT: p<.0001; adj. p=0.0007), with post-GMLT vagal ratio 
not differing significantly from pre-GMLT levels (p=0.2283; adj. p=0.9185).  Aβ+ 
group did not consistently show any change in vagal ratio at any point during 
testing (pre- vs. GMLT p=0.1837, GMLT vs. post- p=0.2221, post- vs. pre-GMLT 
p=0.7883; adj. p =0.9985 for all).  Further, the increased vagal ratio during the 
cognitive stress condition (p=0.0099; adj. p=0.0304) and subsequent decreases 
(p=0.0013; adj. p=0.0007) for the Aβ- group differed significantly from the Aβ+ 
group. 
 
Figure 3. Plots of RSA in participants testing negative (blue, left) and positive (red, 
right) for Aβ (ACC) as a function of pre-, during, and post-GMLT testing. Least 
squares means (large circles) and 95% confidence intervals were adjusted for age. 
Small circles indicate the raw individual patient values for each phase of testing in 
order to convey the variability in values between patients. Light gray lines 
illustrate the individual changes relative to pre-GMLT testing (normalized to pre-
GMLT by subtraction) in order to convey the consistency of within-subject 
changes. Aβ- subjects showed a significant increase in RSA during the cognitive 
task condition, relative to either of the two at-rest conditions (Pre-GMLT: p<.0001; 
adj. p<.0001; Post-GMLT: p=<.0001; adj. p=0.0003), with post-GMLT RSA not 
differing significantly from pre-GMLT levels (p=0.2471; adj. p=1.0).  As with the 
vagal ratio measure, those in the Aβ+ group did not consistently show any change 
in RSA at any point during testing (pre- vs. GMLT p=0.6321, GMLT vs. post- 
p=0.7719, post- vs. pre-GMLT p=0.8510; adj. p =1.0 for all). Further, the 
increased RSA scores during the cognitive stress condition (p=0.0021; adj. 
p=0.0104) were significantly larger for the Aβ- group compared to the Aβ+ group. 
The subsequent decrease in RSA for the Aβ+ group after the cognitive stress were 
significantly greater than for the Aβ- group prior to adjustment, but not after 
multiplicity adjustment (p=0.0304; adj. p=0.0913). 
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Structured Abstract  
 
Introduction: We conducted a 27-month longitudinal study of mid-life adults with 
preclinical Alzheimer’s disease (AD), using Spectral domain Optical Coherence 
Tomography (SD-OCT) to compare changes in volume and thickness in all retinal 
neuronal layers to those of age-matched healthy control subjects.  
 
Methods: Fifty-six older adults (mean age = 65.36 years) with multiple risk 
factors for AD completed SD-OCT retinal imaging and cognitive testing at 
baseline.  Twenty-seven months later they completed the same exams as well as an 
18F-Florbetapir PET imaging study.  
Results: Compared to healthy control subjects, those in the preclinical stage of AD 
showed a significant decrease in macular retinal nerve fibre layer (mRNFL) 
volume, over a 27-month follow-up interval period, as well as a decrease in outer 
nuclear layer (ONL) and inner plexiform layer (IPL) volumes and thickness in the 
inferior quadrant. However, only the mRNFL volume was linearly related to 
neocortical PET amyloid SUVr after controlling for any main effects of age 
(R2=0.103; ρ = 0.017). Furthermore, the magnitude of mRNFL volume reduction 
was significantly correlated with performance on a task of participants’ abilities to 
efficiently integrate visual and auditory speech information (McGurk effect).  
 
Discussion: We observed a decrease in mRNFL, ONL and IPL volumes, in 
preclinical AD relative to controls. Moreover, the largely myelinated axonal loss in 
the RNFL is related to increased neocortical Aβ accumulation after controlling for 
age. Volume loss in the RNFL, during the preclinical stage, is not related to 
performance on measures of episodic memory or problem solving. However, this 
retinal change does appear to be modestly related to relative decrements in 
performance on a measure of audiovisual integration efficiency that has been 
recently advanced as a possible early cognitive marker of mild cognitive 
impairment. 
 
 
Keywords  
Pre-clinical, Alzheimer’s disease, retinal, cognition, RNFL, OCT, Optical 
Coherence Tomography, McGurk Effect, Amyloid 
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Research in Context 
 
 
Systematic Review 
We reviewed 15+ years of literature on the relationship between the morphology 
of retinal neuronal layers and Alzheimer’s disease (AD), and the evidence of 
disease-related retinal change over the progression of AD.  This literature is mixed, 
with inconsistent findings, and it consists mostly of cross-sectional studies in 
patients with symptomatic disease. We were unable to identify prior publications 
that have sought to explore within-subjects longitudinal change in retinal 
morphology during the preclinical stage of AD for all retinal neuronal layers. 
 
Interpretation 
After controlling for expected effects of normal aging, we observed a decrease in 
the macular region of the RNFL (mRNFL) that is moderately correlated with PET 
imaging evidence of amyloid aggregation. Volume loss in the mRNFL, during the 
preclinical stage, is not related to performance on measures of episodic memory or 
problem solving, but is modestly related to relative decrements in performance on 
a measure of visual-auditory integration of new information. This may be a first 
report of neuronal retinal layer volumetric changes in a within-subjects, 
prospective and longitudinal study of preclinical AD. 
 
Future directions 
Larger populations of participants, across the entire disease severity spectrum 
(from healthy controls to mild AD), should be followed for an even longer time 
interval in order to better model the natural history of retinal anatomic changes 
over the entire course of disease progression.  Additional imaging methods could 
improve our understanding of the mechanisms of disease-related retinal change, 
such as OCT Angiography and scanning polarimetry.  
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Background 
 
The formation of the eye begins in the third week of human embryologic 
development, with the retina being a crucial component of the ocular globe and the 
central nervous system (CNS). The retina is derived from pluripotent 
neuroectodermal cells that migrate from the diencephalic invagination of the neural 
tube [1], and so it is structurally, physiologically, and functionally brain tissue — 
with the retina sometimes described as a “protrusion” from the brain.  As is the 
case throughout the neocortex, the retina consists of discrete neuronal cell layers, 
with multiple types of neurons and neurotransmitter systems, glial cells and 
microvasculature. Unlike the rest of the CNS, however, the retinal neuronal cell 
layers can be non-invasively visualized through high-resolution optical methods 
such as spectral domain optical coherence tomography (SD-OCT) [2].   
A recent review [3] cites the wide variety of retinal biomarkers that have been 
explored in patients with Alzheimer’s disease (AD), ranging from retinal 
anatomical and vascular markers, to curcumin binding studies [4], retinal oxymetry 
and electroretinogram (ERG) studies. Clinically, it is reasonable to suspect the 
presence of early ocular involvement in AD because visual system changes such as 
decreased vision, abnormal pupillary reaction, visual field changes, motion 
detection abnormalities, impaired color vision, and decreased contrast sensitivity 
have been identified in mild-to-moderate AD [3,5]. 
 SD-OCT allows for the precise segmentation and measurement of the 
retinal cell layers, thereby promoting exploration of neuronal changes that might 
be directly related to specific neurodegenerative diseases.  Over the past two 
decades there have been over 70 peer-reviewed publications exploring retinal 
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optical coherence tomography (OCT) correlates of Alzheimer’s disease, in 
humans, non-human primates, and other animal models of AD disease. With 
respect to humans, most prior reports have consisted of cross-sectional studies 
comparing groups of AD patients to groups of seemingly “healthy controls”.  
When compared with healthy age-matched controls, patients with AD have 
reduced numbers of ganglion cell axons, and are three times more likely to have an 
increased optic nerve cup-to-disc ratio, a potential consequence of ganglion cell 
and nerve fiber loss [6].  Such reports have confirmed an earlier report of 
substantial loss of ganglion cells in AD patients, based on histopathology of 
autopsy materials [7].  Further, peripapillary retinal nerve fiber layer (pRNFL) 
thickness has been found to be significantly thinner, suggesting the presence of 
optic atrophy in patients with mild cognitive impairment (MCI) and mild-to-
moderate AD when compared with age-matched controls [8]. Reduction of 
macular RNFL volume (mRNFL) also has been identified in AD [9].  The loss of 
RNFL tissue in the retina may constitute an early biomarker of AD. If so, a 
reduction in RNFL thickness or volume may be observed prior to widespread 
damage to the mesiotemporal CNS memory system that is characteristic of AD 
[10,11,12].  
With respect to the RNFL we have surveyed all available literature, 
including those studies relying on other imaging approaches, such as 2D fundus 
photography and histological analyses, and we have found variable reports of 
decreased RNFL and/or ganglion cell layer (GCL) thicknesses in AD and MCI.  A 
search on Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/) was performed (25 
August, 2017) to find all published articles, using the search terms “Alzheimer’s” 
and “retinal layer”.  This search led to 134 papers identified and, of these, only 34 
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papers consisted of human studies that compare retinal layer morphology changes 
in Alzheimer’s patients to healthy individuals (see Table 1). 
Nearly all of these 34 publications resulted from cross-sectional studies 
based on comparisons of cases to putatively ‘healthy controls’.  Most often the 
healthy controls had no biomarker confirmation to indicate that they did not fall 
within the preclinical stage of AD. One study did search for thickness differences 
in all 10 retinal layers [20], with the remaining 33 studies concentrating on 
measurement differences for the mRNFL, pRNFL and the GCL. Of note, the GCL 
was only once reported as a single layer [20], being most often considered in 
conjunction with an adjacent cell layer, either as the ganglion cell – inner 
plexiform layer complex (GC-IPL complex) or as the retinal nerve fiber layer – 
GCL complex (RGCL or GCC).   
From the 33 papers seeking to compare group differences for the RNFL, 29 
found RNFL thinning in AD compared with age-matched controls (see Table 1).  
Only seven of these 29 published reports appear to have accounted for participant 
age as a statistical co-variate in their analyses. This is important because there is 
normal age-related thinning of the RNFL and other retinal layers [44].  Of these 
seven publications that did account for effects of aging, one determined that the 
observed thinning was due primarily to the main effect of aging rather than disease 
burden [26]; one study found RNFL thinning in MCI but not in AD [30]; two 
studies reported RNFL thinning solely in one or two specific quadrants [13, 32]; 
and three studies reported robust disease-burden after accounting for age [15, 17, 
18].  Only two of the 33 reviewed studies reported within- subjects longitudinal 
results (both in symptomatic AD patients vs. controls), and they both reported 
increased RNFL thinning compared with controls [18, 27].   
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Alzheimer’s disease-related amyloid-beta (Aβ) plaques can start to 
accumulate abnormally in the brain up to 20 years before symptom onset, and this 
stage is classified as pre-clinical AD [45,46]. Only two of the studies reviewed 
above, both relying solely on cross-sectional data, recruited individuals in the pre-
clinical stage of the disease. One from the same larger study that we draw from in 
the current report [16], found a thicker inner plexiform layer (IPL) in preclinical 
AD compared with healthy controls.  Another study [14] found no difference in the 
RNFL thickness between AD, preclinical AD and healthy controls. Golzan and 
colleagues reported a significant difference in the RGCL thickness across the three 
groups, and yet they found no association between retinal structural measurements 
and PET Aβ binding in the neocortex. Aside from these two cross-sectional studies 
of preclinical AD [14, 16], none of the other published reports compared PET 
imaging evidence of neocortical amyloidosis with the retinal OCT measurements 
for this earliest stage of the disease.  
 
-------------------------------------------- 
Insert Table 1 About Here 
-------------------------------------------- 
 
 In this current report, we followed the same cohort of subjects at high-risk 
for preclinical AD over 27 months to explore changes in all retinal neuronal layers 
and we relate these findings to PET imaging evidence of cortical amyloid 
aggregation in the same participants.    
In our current study, we compared morphological changes in retina with 
cognitive performance.  Previous studies examining this relationship have relied on 
the Mini-Mental State Exam (MMSE) as a screening measure of general cognitive 
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function, and these studies have led to conflicting results. Some studies have found 
no relationship between RNFL thinning and MMSE in AD [41, 47] and MCI [39], 
while one study found a correlation between RNFL thickness and MMSE scores in 
MCI [29]. Another study reported a correlation between macular volume thinning 
(whole retina) and MMSE scores in patients with AD [9].  For individuals in the 
pre-clinical stage of disease severity, the MMSE would be a poor choice as a 
cognitive marker, due to several psychometric limitations for this test [48].  With 
respect to the MCI stage of disease severity, two prior investigators have reported 
surprisingly inverse relationships between performance on measures of verbal 
episodic memory and RNFL thickness [49, 50]. Importantly, both of these studies 
reported cross-sectional data, and it is unclear as to whether this inverse 
relationship (that is, relatively enhanced performance on verbal episodic memory 
tests associated with relatively diminished RNFL thicknesses) would persist if 
participants were followed longitudinally and as the disease progresses. 
Our intent was to explore this very question, that of the relationship 
between cognitive functioning and evidence of morphologic change in the retina, 
over the course of several years, and within the very early, pre-clinical stage of the 
disease.  Based on prior literature in this specific patient population, we chose the 
Groton Maze Learning Test (GMLT) as a measure of learning efficiency, problem 
solving and working memory [51,52], and the International Shopping List Test 
(ISLT) to measure verbal episodic memory [53, 54]. Finally, we administered an 
audiovisual McGurk task, a speech processing paradigm that relies on the integrity 
of white matter tracts that underlie corticocortical connectivity, as prior work has 
shown disruption of functional integration for posterior sensory regions in AD [55, 
56].  Because alterations in white matter integrity may occur in early stages of the 
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disease [57, 58, 59], similar early changes in the RNFL - which is comprised 
mostly of myelinated axons from the cell bodies in the GCL - might be directly 
related  to the loss of white matter tracts in the cortex, and hence correlate with 
performance on this cognitive task that specifically assesses corticocortical 
connectivity and has recently been advanced as a potential biomarker of early stage 
AD pathology [60].  
 
Methods 
2.1. Participants 
A total of Fifty-six adults aged between age 55 and 75 years (mean age = 
65.36 years old) with two well-established risk factors for AD, namely, a self-
reported first-degree family history of the disease and self-identification of 
subjective memory concerns, were recruited using a selection process described 
previously [61].  All participants underwent a detailed medical screening 
interview. Exclusion criteria included a diagnosis of MCI or AD following the 
National Institute on Aging - Alzheimer’s Association (NIA-AA) diagnostic 
criteria [45, 62], history of neurological or psychiatric disorder, any significant 
systemic illness or unstable medical condition (e.g., active cardiovascular disease), 
and current use of any medications known to affect cognition (e.g., use of sedative 
narcotics). Subjects with histories of cataract surgery, corneal (LASIK) surgery, 
AMD, or subjects with known ophthalmic pathology were excluded. Inclusion 
criteria included having an MMSE score of > 27 and performance within normal 
limits on a battery of cognitive tests described previously (listed in Table 2) 
[63,64].  Since RNFL thinning is a characteristic of glaucoma, subjects with 
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glaucoma were excluded. Participants were also excluded if they had a history of 
optic neuritis, intraocular surgery apart from cataract extraction, or a history of 
visual loss apart from refractive error as these conditions may affect the RNFL 
thickness [65, 66, 67].  Additionally, upon examining the OCTs, we excluded any 
eye OCT that had evidence of epiretinal membrane [68].   
-------------------------------------------- 
Insert Table 2 About Here 
-------------------------------------------- 
 
All participants live independently, most were engaged in full-time or part 
time employment, and many were caretakers for a parent with AD.  The amount of 
neocortical beta-amyloid protein aggregation (Aβ) and apolipoprotein E (APOE) 
genotype were unknown at the time of assessment and were not used to determine 
enrollment. Although Aβ status and APOE genotyping were conducted as a part of 
the study protocol, researchers remained blinded to these results throughout 
testing.  
From this larger sample, we identified 15 participants who were 
categorized as presenting with preclinical stage disease based on evidence of both 
1) elevated neocortical beta-amyloid burden as determined by PET amyloid 
imaging [45,46]; and 2) relative cognitive impairments in response to a challenge 
with a very low-dose muscarinic anticholinergics [59, 63].  
The study was approved by and complied with the regulations of Rhode 
Island Hospital’s Institutional Review Board, and all participants provided written 
informed consent in accordance with the Declaration of Helsinki. The study 
complied with (HIPAA) regulations. 
 
2.2. Aβ PET imaging 
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To assess neocortical amyloid burden, all participants had an Aβ PET scan 
at baseline and another at 27-month visit. A 370MBq (10 mCi 1/2 10%) bolus 
injection of 18F-florbetapir was administered intravenously. Approximately 50 
minutes’ post-injection, a 20-minute PET scan was performed with head CT scan 
for attenuation correction purposes. Images were obtained using a 128X128 matrix 
and reconstructed using iterative or row action maximization likelihood 
algorithms. PET standardized uptake value (SUV) data were summed and 
normalized to the whole cerebellum SUV, resulting in a region-to-cerebellum ratio 
termed SUV ratio (SUVr).  
An SUVr threshold of 1.1 or greater was used to discriminate between Aβ+ 
and Aβ-. These SUVr calculations were performed using the MIMneuro software, 
with a normative database of 74 healthy normal individuals (48 males, 26 females), 
aged between the ages of 18–50 years, who all had negative amyloid scans on 
visual assessment [69]. For all cases, Aβ positivity was confirmed by consensus 
over-read by two board-certified radiologists who were also board certified in 
nuclear medicine. 
 
2.3. SD-OCT imaging 
Participants were administered two drops of tropicamide (Mydriacyl 1%) 
per eye for pupil dilation before OCT imaging. The Heidelberg SPECTRALIS SD-
OCT was used to acquire retinal OCT scans of the optic nerve head and the macula 
for the right and left eyes of all participants at baseline and 27 months.  Heidelberg 
SPECTRALIS has automatic segmentation and quantification of retinal layers, 
uses the eye-tracking image alignment for repeated measures (TruTrack; 
Heidelberg Engineering, Inc).  Outcome measures for the SD-OCT imaging, 
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following the Anatomic Positioning System (APS) protocol sequences, included 
pRNFL, mRNFL, GCL, inner plexiform layer (IPL), inner nuclear layer (INL), 
outer plexiform layer (OPL) and outer nuclear layer (ONL). For each individual 
participant, the volume and thickness of all retinal neuronal layers were measured 
and averaged for both eyes.  
The mean macular thickness of each retinal layer was measured at 4 sectors 
(superior, inferior, nasal, and temporal) leading to a macular volume for each 
retinal layer (see Fig.1). For the pRNFL, the mean thickness also was calculated in 
4 sectors (superior, inferior, nasal, and temporal) centered in the optic nerve and 
the thickness of all areas were averaged to result in the average thickness. 
-------------------------------------------- 
Insert Figure 1 About Here 
-------------------------------------------- 
 
The volumes for all layers were obtained separately, across the entire 
macular region extending 3.45 mm from the center of the fovea.  Mean volumes 
(mm3) for reach layer and thickness (μm) for each quadrant (right and left eyes 
averaged) were computed for both the baseline and the 27-month time points.  The 
difference between these two exam time points was obtained for each subject and 
for each layer.  Multicolor imaging, which uses individual laser wavelenghts [70] 
to characterize anatomic and pathologic detail at different retinal depths, served to 
identify and exclude individuals with background diabetic retinopathy and retinal 
microbleeds within the region of interest. 
 
2.4. Cognitive Assessment 
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The Groton Maze Learning Test (GMLT; http://www.cogstate.com) is a 
computer administered hidden maze test, designed by one of the authors (P.J.S.) to 
measure spatial working memory and problem-solving functions [71]. The GMLT 
has been described previously both in terms of performance within the context of 
studies with healthy elderly adults [51, 72,73], as well as in MCI [74].  
Additionally, all subjects completed the International Shopping List Test 
(ISLT; www.cogstate.com) as a measure of verbal episodic memory [75], the 
MMSE as a measure of general cognitive function, and the Memory Complaint 
Questionnaire (MAC-Q) [76] as a measure of subjective memory complaints. 
As noted above, we also administered an audiovisual McGurk Task that has 
recently been described as a potential new marker of early-stage AD [60]. The 
McGurk effect is a compelling misperception in which discrepant visual and 
auditory speech information presented simultaneously results in the listener 
hearing a fused audiovisual speech sound, rather than the veridical auditory sound 
(e.g., /ba/ auditory + /ga/ visual is heard as /da/ rather than /ba/) [77]. The integrity 
and efficiency of the audiovisual integration process can be measured by 
comparing accuracy and response times to identify the auditory information under 
Congruent (matching audio and visual components) and Incongruent (conflicting 
audio and visual components) conditions. For the purpose of this study, we 
focused on a measure of integration efficiency, defined as the proportional increase 
in response time from Congruent to Incongruent conditions for the weaker 
McGurk stimulus in this task. This stimulus condition was particularly sensitive at 
discriminating patients diagnosed with amnestic mild cognitive impairment (MCI) 
from healthy elderly [60]. Higher efficiency scores reflect greater sensitivity to 
binding strength. 
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All cognitive measures were performed by trained staff supervised by a 
licensed clinical neuropsychologist. 
 
2.5. Statistical Methods 
For the demographic variables, t-tests were performed for each variable 
between the preclinical AD and healthy control groups. For the layers RNFL 
(macular and peripapillary regions), GCL, ONL, outer plexiform layer, inner 
nuclear layer and IPL paired 1-sided significance level of 0.05 t-tests were 
performed, and the effects sizes for each comparison were computed with the 
Cohen’s d statistic.  For each layer, the differences between baseline and 27-month 
measurements, and between Aβ+ and Aβ- subjects for the total volume, and the 
thickness of the average and the quadrants (N3.45, T3.45, S3.45, I3.45) were 
computed. Linear regression models were performed with neocortical PET 
imaging SUVr entered as a response variable, and retinal layer measures as the 
explanatory variables, and covarying for effects of normal aging. Although age 
was not significantly different between groups, it is a key predictor of volumetric 
loss over time in the macula.  In order to assess whether a correlation exists 
between retinal layer thickness and any of the cognitive tests, linear regression 
analysis (Pearson's test) was adopted, a p value less than 0.05 was considered 
significant, and the magnitude of differences was quantified using Cohen’s d.  
 
Results 
3.1. Sample Demographics 
Of the 56 participants enrolled, 35 were female and 11 of them were amyloid 
positive on PET imaging.  There were no significant differences between Aβ+ and 
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Aβ- groups with respect to sex (p=0.311).  Likewise, there were no group 
differences in the proportion of individuals with the APOE Ɛ4 genetic risk marker 
for AD.  The mean age for the total sample was 65.36 years old and this sample 
had an average of 17.31 years of education. All relevant demographic information, 
for both groups, is provided in Table 2.  There were no group differences with 
respect to body mass index, subjective memory complaints, cognitive performance 
at baseline exam (on any of the tests described above).  By definition, both groups 
significantly differed with respect to neocortical amyloid aggregation as measured 
via PET imaging (p = 0.000). 
With respect to genetic risk for AD, eight of 15 individuals (53%) in the 
preclinical AD group (Florbetapir PET SUVr scores ≥1.10) had at least one copy 
of the APOE ε4 allele, whereas 20 of 45 individuals (45%) in the control group 
(Florbetapir PET SUVr scores < 1.10) had at least one copy of the APOE ε4 allele. 
Hence, roughly half of the subjects in each group presented with this additional 
risk factor for AD, but due to small sample sizes we were not able to further 
evaluate the specific effect of APOE genetic risk on retinal layers measurements. 
Subject demographic information, for both groups, is provided in Table 2. 
 
3.2. Retinal Layer Measurements 
 At baseline exam, no group differences were found with respect to either the 
thicknesses of any macular quadrant for any neuronal layer, nor were there any 
group differences observed with respect to total volumes for each layer in the same 
region (Table 3).   
-------------------------------------------- 
Insert Table 3 About Here 
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Change over the 27-month follow-up period, for each of these measures, 
was calculated by subtracting the volumes (mm3) and thickness (μm) obtained at 
the baseline visit from the same measurements obtained at the 27-month visit.  As 
shown in Table 4, a significant group difference was found for the mRNFL 
(p=0.050), ONL (p=0.026) and IPL volumes (p=0.020).  In all cases, the pre-
clinical AD group showed a larger reduction in volume over this time period, 
compared to the healthy control group, and in all cases these group differences 
were of a moderate effect size. The only significant changes observed in thickness 
after controlling for effects of age were in the inferior quadrant of the ONL (0.026) 
and IPL (p=0.028), with a larger reduction in the preclinical group, and in the 
temporal quadrant of the OPL (0.040), with a larger increase in the preclinical 
group compared to the control.  
Considering each subject group separately, the change from baseline to 27 
months in the total volume (mm3) of the mRNFL was significantly decreased for 
the pre-clinical AD group (-0.032±0.003, p=0.002) as well as for the healthy 
control group (-0.0190±0.003, p=0.03).  With respect to the pRNFL, although we 
found an overall non-significant difference in the magnitude of the thinning 
between the two groups, over the 27-month period, we observed substantially 
greater ranges of variance of measurements for both groups, as reflected by 
markedly larger standard deviations (SD) of measurement (Table 3).  This region 
of the pRNFL is thought to have greater within-subject and between-subject 
variability because it contains a multitude of larger diameter blood vessels, 
particularly with respect to vascular innervation within the regions of the superior 
and inferior arcuate bundles, individual differences in optic canal sizes, the 
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presence or absence of space-occupying nerve head drusen, and other individual 
differences in this region [78]. 
 
3.3. Retinal Layer Change in Relation to Neocortical Amyloid Aggregation 
 A multivariate linear regression model, controlling for participant age, with total 
neocortical PET amyloid ligand binding (SUVr) entered as the dependent measure was 
conducted. Macular RNFL (mRNFL) volume change, over the 27-month study interval, 
accounted for 10% of the variance in PET amyloid neocortical binding at the end of the 
study (Adj R2 = 0.106, ρ = 0.017; Fig 2).  By comparison, change in the GCL over the 
same time was related to participant age (ρ=0.05), but not significantly related to PET 
amyloid SUVr (ρ=0.78).  For all neuronal cell layers, other than the mRNFL, the observed 
change over time was not related to Neocortical PET Amyloid SUVr. 
 
3.4. Retinal Layer Change in Relation to Cognitive Performance 
 
There were no significant relationships found between volume reductions for 
any of the retinal layers over 27 months and performance on measures of spatial 
working memory and learning efficiency (GMLT) or on a measure of word-list 
learning and episodic verbal memory (ISLT) (p>0.005).   
-------------------------------------------- 
Insert Table 4 About Here 
-------------------------------------------- 
 
However, an interesting correlation was found between the magnitude of 
mRNFL volume reductions and increasing difficulties on the McGurk task of 
efficiency for audiovisual integration.  That is, individuals with greater volume 
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reduction in mRNFL showed reduced sensitivity to the binding strength of the 
audiovisual stimulus (ρ = 0.037, 1-tailed; Fig 3). 
 
Discussion 
The average RNFL thicknesses for both groups in our study are similar to the 
control groups reported by others [5, 39] as well as to the measurements obtained 
by Golzan and colleagues in their preclinical AD [14].  Likewise, our OCT 
measurements of the GCL and IPL layers are quite similar to those reported by 
others [22].   
-------------------------------------------- 
Insert Fig. 2. About Here 
-------------------------------------------- 
 
Of the prior studies we reviewed and described above, Garcia-Martin and 
colleagues reported retinal layer thickness values that differed substantially from 
both our measurements as well as from most other published reports [20].  
Most published research on this topic have relied on cross-sectional study 
designs, with measurements of the thickness and volume of various retinal layers 
at a single point in time.  Such studies are likely to be limited in their ability to 
identify retinal markers of the preclinical stage of AD, as such individuals are still 
relatively young and such between-groups comparisons have not generally 
accounted for a variety of confounding variables including, but not limited to, 
effects of sex differences, ethnicity, axial length, optic disc area, and refractive 
status on OCT measurements [44, 79, 80, 81].   
-------------------------------------------- 
Insert Fig. 3. About Here 
-------------------------------------------- 
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Insert Table 5 About Here 
-------------------------------------------- 
 
Hence, we performed this within-subjects longitudinal study to measure 
individuals’ structural parameters that can be reliably re-measured at different 
time points using the Eye Tracker software for SPECTRALIS SD-OCT [82]; we 
then calculated the difference after 27 months of all measures collected (Table 4) 
for the preclinical AD and the healthy control group.  To our knowledge, this is the 
first attempt to both explore within-subject change in retinal neuronal layer structures, in 
the preclinical stage of AD, and to relate any such observed changes to performance on a 
cognitive assay that has been shown to be sensitive to detection of early-stage disease 
burden.  Our findings suggest that a decrease in mRNFL volume is the earliest 
detectable structural retinal change associated with AD.  Moreover, this change in 
mRNFL volume is related with neocortical Aβ accumulation in very early AD 
(Fig. 1), even after correcting for expected age-related decline [83] (Table 5).  By 
comparison, the decrease in GCL volume observed over the same time period was 
principally related to the effects of aging (ρ=0.05) rather than due to cortical beta-
amyloid aggregation (ρ=0.78), at least during this earliest detectable stage of 
disease progression.  
The macular region of the retina is physiologically very active in healthy 
normal eyes [7], and this “hyperexcitation” might be diminishing in the 
preclinical stage of AD.  In support of this hypothesis, postmortem histological 
studies have found prominent pathological alteration of retinal ganglion cells 
(RGCs) in the macular region in AD patients [26, 84] as well as a preferential loss 
of larger axons, suggesting early involvement of the magnocellular RGCs in AD 
as they contribute large caliber fibers to the optic nerve [85].  The RNFL is 
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adjacent to the GCL and it is composed largely of ganglion cell axons that are 
organized in superior and inferior arcuate bundles, and the papillomacular bundle 
(PMB), that lead to the optic nerve.  Early in multiple sclerosis there is 
demyelination without axonal loss. Likewise, the mRNFL may be thinned due to 
demyelination, and possibly only when there is axonal loss will we see loss of 
ganglion cells (GCL). Our results suggest early demyelination in the RNFL in the 
preclinical stage of AD, and our data confirm at least one other report of mRNFL 
changes occuring prior to pRNFL changes in AD [86].  Moreover, there is some 
suggestion that this might be most readily observed in the superior quadrant of the 
mRNFL [86] and this would make sense in light of at least one clinical report of 
preferential inferior visual field loss in AD [87].  However, in a meta-analysis of 
17 studies comparing AD patients with healthy controls and five studies 
comparing individuals with mild cognitive impairment (MCI) with controls, there 
were significant decreases in all four quadrants compared to controls, thus 
suggesting that the degenerative process affects the entire macular region [8].  
There have now been ample work showing that there is GCL thinning 
observed in the symptomatic stage of AD [5,15, 22]. Moreover, Martin et al. [20] 
studied 150 patients with AD and 75 age-matched controls to model how changes 
in RNFL and other neuronal cell layers’ thicknesses are associated with disease 
duration and severity.  This work suggests that there is axonal degeneration in the 
RNFL early in the disease followed by degenerative changes to the cell bodies in 
the GCL and then progression to deeper neuronal layers [20].  This progressive 
pattern of mRNFL loss prior to GCL loss is further confirmed by our results 
reported above.  Additionally, we found that only loss of mRNFL tissue, and not 
loss in any other neuronal layer, was correlated with beta-amyloid protein 
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aggregation in the cerebral cortex.    These results fit nicely with data from a large 
population-based epidemiological study (Rotterdam Study, 2007-2012) showing 
that having a thinner RNFL at a baseline exam was significantly associated with 
increased risk of later developing dementia [88].  
 
4.1. Relationship of RNFL Thinning to Cognitive Function in Preclinical AD 
Contrary to a few prior reports [49, 50, 89], we did not observe any 
correlation between any retinal layer changes and change in either episodic verbal 
memory (ISLT) or for performance on a working memory and reasoning task for 
visuospatial information (GMLT). However, because white matter degeneration is 
readily observable in the early stages of AD [90], and the cerebral white matter is 
principally composed of myelinated axons and glial cells – as is the retinal RNFL – 
we chose to administer a cognitive task that is putatively sensitive to functional 
disruption of corticocortical connections caused by disruption of white matter 
integrity [60].  Both prodromal and preclinical AD patients with high beta-amyloid 
burden have been previously found to display changes in audiovisual integration 
efficiency that are likely due to AD-related disruptions in functional connectivity 
between posterior sensory regions.  Using McGurk-like audiovisual speech stimuli 
(i.e., video clips of an individual mouthing a speech sound while the audio channel 
provides either consistent or inconsistent auditory speech information), we found 
that greater volume reduction in mRNFL was significantly associated with reduced 
sensitivity to the binding strength of the audiovisual stimulus (Fig. 2).  While 
healthy individuals typically show faster response times to consistent stimuli than 
inconsistent stimuli (i.e., response times are faster when the auditory and visual 
components provide the same compared to conflicting speech information), we 
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found that this response time difference decreased with greater RNFL volume 
reduction. In fact, greater volume reduction in mRNFL was significantly 
associated with reduced sensitivity to the binding strength of the audiovisual 
stimulus, suggesting that mRNFL volume reduction is related to white matter loss. 
Consistent with previous findings [60], this reduced sensitivity may reflect subtle 
disruptions of corticocortical projections within unimodal and heteromodal sensory 
cortices that indicate individual risk of AD.   
 
4.2. Change in Retinal Neuronal Layers, Other than the RNFL, in Preclinical AD 
As noted above, we observed significant changes in ONL (p=0.026) and 
IPL volumes (p=.002), and inferior quadrant thicknesses for these same layers, 
respectively (ρ=.026; ρ=0.028), in the preclinical AD group compared to the 
controls, over 27 months. However, neither of these changes were related to PET 
imaging severity of neocortical amyloidosis at the end of the 27-month interval 
(Table 5).  We have previously reported, with the same cohort of subjects at their 
baseline examinations, an increase in the IPL volume in preclinical AD that may 
be related to either Aβ deposition and/or an inflammatory process [16].  Twenty-
seven months later we have now found evidence of tissue loss in the IPL, within 
our preclinical group relative to controls, suggesting that although there may be an 
initial early stage of IPL volume increase due to an inflammatory process, there is 
nonetheless some volume loss in this structure over continued disease progression.   
Finally, the ONL consists of photoreceptor cell bodies and thinning of this 
layer has previously been shown in patients with age-related macular degeneration 
in association with tears in the retinal pigment epithelium [91].  In the context of 
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early AD, we believe that our observation of tissue loss in the ONL could suggest 
retrograde transsynaptic degeneration, but future analysis would be necessary.   
 
Conclusion and Future Directions 
To our knowledge this is a first report of a within-subjects, prospective, 
longitudinal study of retinal anatomic changes in the preclinical stage of AD.  We 
have found that thinning of the mRNFL may be the earliest anatomic marker of 
retinal neuronal loss in the preclinical stage of AD, and such loss appears to 
account for 10% of the variance in observed PET imaging measurement of 
neocortical amyloidosis.  Whereas most reports have relied on clinical 
examinations for determining disease burden, our study used PET imaging 
biomarker of disease burden.  Our study is limited by a small sample size, and so 
these findings require replication in a larger patient population.  Secondly, we 
chose to recruit participants who were at high risk for the very early stages of the 
disease, that is, during a prodromal stage that is defined by a relative absence of 
readily identifiable cognitive and/or functional impairments, as well as by 
biomarker evidence of disease burden that is subtle and for which clear diagnostic 
criteria have not yet been established [46]. Third, retinal imaging is not only being 
studied to identify novel biomarkers for this neurodegenerative disease, but 
changes in the GCL and RNFL thickness have also been reported in Parkinson’s 
disease and multiple sclerosis [92, 93, 94, 95]. 
Future work on this topic will require the recruitment of larger populations 
of participants, across the entire disease severity spectrum (from healthy controls 
to mild AD), and ideally such a large cohort should be followed for an even longer 
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time interval in order to better model the natural history of retinal anatomic 
changes over the entire course of disease progression.  Additional imaging 
modalities should be included in such a study (e.g., OCT Angiography), as retinal 
blood flow appears to be reduced in MCI and AD [19,40], and the disease has been 
associated with a retinal venular stenosis, reduced complexity of the branching 
pattern and geometry, and reduced tortuous venules [96].  We also would 
recommend inclusion of scanning laser polarimetry (SLP) methods to measure 
RNFL retardance in preclinical AD because, in glaucoma, RNFL retardance seems 
to occur before actual RNFL thinning [97]. The mechanisms of glaucomatous 
injury appear to be related to damage the integrity of axonal cytoskeletal 
ultrastructure prior to the point of RNFL thinning detectable by OCT [97,98,99]. 
The axonal cytoskeleton disruption that causes RNFL retardance [97] may possibly 
be similar to the effects of Aβ plaques and tau tangles in the AD brain.  
These results point to the first retinal anatomic changes occurring in the 
early stages of AD. Characterizing retinal changes at this stage with a non-invasive 
method will facilitate the search for treatments that can delay or stop the 
progression of AD. This study also demonstrates that, although many different 
approaches have already been taken in this field, there is still much more to 
explore and much that we do not understand with respect to the effects of 
Alzheimer’s disease on the retina. 
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 Table 1. Review of Papers published until 25 July 2017, using the search terms 
“Alzheimer’s” and “retinal layer”.   
 
Publication Layers Results 
Cross 
sectional Subjects 
Age 
matched 
Controls 
Cunha et al., 
2017 [13] 
pRNFL and 
retinal 
thinner pRNFL, and 
superior pericentral 
and peripheral retinal 
sectors Yes AD 
Yes, age 
as 
covariate 
Golzan et al., 
2017 [14] 
RNFL and 
GC-IPL 
RGCL thinner, no 
difference in RNFL Yes 
preclinic
al AD 
Yes, age 
as 
covariate 
Ferrari et 
al.,2017 [15] 
pRNFL and 
GC-IPL thinning Yes 
MCI and 
AD 
Yes, age 
as 
covariate 
Snyder et 
al.,2016 [16] IPL thicker in preclinical Yes 
preclinic
al AD Yes 
Choi et al., 
2016 [17] 
pRNFL and 
GC-IPL 
thinner in the 
temporal quadrant Yes 
MCI and 
AD 
Yes, age 
as 
covariate 
Trebbastoni 
et al., 2016 
[18] pRNFL thinner 
No, 1 
year AD 
Yes, age 
as 
covariate 
Feke 
etal.,2015 
[19] pRNFL no difference Yes 
MCI and 
AD Yes 
Cunha et 
al.,2016 [5] 
Macular and 
GCL+ (GC-
IPL) thinner Yes AD Yes 
Garcia-Martin 
et al., 2016 
[20] 
pRNFL, GCL, 
INL, IPL, 
ONL, OPL 
RNFL, GCL and IPL 
thinner Yes AD Yes 
Pillai et al.,  
2016 [21] 
pRNFL, 
macular and 
GC-IPL no difference Yes 
MCI and 
AD Yes 
Eraslan et al., 
2015 [22] 
pRNFL and 
GCC (RGCL) thinner Yes AD Yes 
Güneş et al., 
2015 [23] pRNFL thinner Yes AD Yes 
Cesareo et al., 
2015 [24] pRNFL thinner Yes AD Yes 
 129 
 
Salobrar-
Garcia et al., 
2015 [25] 
pRNFL and 
macular thinner Yes AD Yes 
La Morgia et 
al.,2016 [26] pRNFL age-related thinner Yes AD 
Yes, age 
as 
covariate 
Shi et al., 
2016 [27] pRNFL 
thinner in the inferior 
quadrant 
No, 27 
months AD Yes 
Liu et al., 
2015 [28] pRNFL 
thinner in the 
superior and superior 
quadrant Yes 
MCI and 
AD Yes 
Oktem et al., 
2015 [29] pRNFL 
thinner, but no 
differences between 
MCI and AD Yes 
MCI and 
AD Yes 
Gao et al., 
2015 [30] 
pRNFL and 
macula 
lutea 
thinner specially in 
MCI Yes 
MCI and 
AD 
Yes, age 
as 
covariate 
Cheung et al., 
2015 [31] 
pRNFL and 
GC-IPL 
thinner pRNFL 
superior quadrant, 
MCI had thinner GC-
IPL Yes 
MCI and 
AD Yes 
Kromer et al., 
2014 [32] pRNFL 
thinner in nasal 
superior Yes AD 
Yes, age 
as 
covariate 
Bambo et al., 
2014 [33] pRNFL 
thinner in the inferior 
and inferiotemporal Yes AD Yes 
Marziani et 
al., 2013 [34]  pRNFL +GCL thinner Yes AD Yes 
Kirbas et al., 
2013 [35] pRNFL thinner Yes AD Yes 
Moschos et 
al., 2012 [36] 
pRNFL and 
macular thinner Yes AD Yes 
Kesler et al., 
2011 [37] pRNFL thinner Yes 
MCI and 
AD Yes 
Lu et al., 2010 
[10] pRNFL thinner Yes AD Yes 
Chi et al., 
2010 [38] pRNFL thinner Yes AD Yes 
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Paquet et al., 
2007 [39] pRNFL 
thinner, but no 
differences in MCI 
and AD Yes 
MCI and 
AD Yes 
Berisha et 
al.,2007 [40] pRNFL 
thinner in the 
superior quadrant Yes AD Yes 
Iseri et al., 
2006 [9] 
pRNFL and 
macula thinner Yes AD Yes 
Parisi et al., 
2001 [41] pRNFL thinner Yes AD Yes 
Kergoat et al., 
2001 [42] pRNFL No differences Yes AD Yes 
Hedges et al., 
1996 [43] pRNFL 
thinner in the 
superior quadrants Yes AD Yes 
Abbreviations: AD, Alzheimer's disease; GCL, ganglion cell layer; GC-IPL, ganglion 
cell–inner plexiform layer complex; INL, inner nuclear layer; IPL, inner plexiform layer; 
MCI, mild cognitive impairment; ONL, outer nuclear layer; OPL, outer plexiform layer; 
pRNFL, peripapillary retinal nerve fiber layer; RGCL (or GCC), retinal nerve fiber layer–
GCL complex; RNFL, retinal nerve fiber layer. 
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Table 2. Demographic Characteristics 
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Abbreviations: APOE, apolipoprotein E; GDS, Geriatric Depression Scale; GMLT, 
GrotonMaze Learning Test; ISLT, International Shopping List Test;MAC-Q, Memory 
Complaint Questionnaire; MMSE, Mini–Mental State Examination; PET, positron 
emission tomography; SUVr, standardized uptake value ratio.Bold values denote 
significant group differences. 
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Table 3. Baseline Retinal Measures by Analysis Group 
 
  Retinal Measures  Preclinical (n=15)  Control (n=41)  p-value 
mRNFL     
total volume (mm3) 0.227±0.021 0.231±0.025 0.283 
average thickness 28.58±3.08 28.92±3.57 0.383 
Inferior  33.04±3.53 32.69±4.39 0.599 
Nasal  28.87±3.87 29.12±4.70 0.433 
Superior  32.12±4.42 32.74±5.10 0.353 
Temporal  20.29±1.20 21.12±2.76 0.157 
pRNFL     
average thickness 103.36±5.36 101.48±9.76 0.726 
Inferior 134.25±8.15 129.05±13.49 0.882 
Nasal 83.04±17.36 85.3±19.88 0.368 
Superior 127.45±10.32 124.17±13.72 0.765 
Temporal 67.86±11.07 67.71±11.68 0.612 
GCL     
total volume (mm3) 0.444±0.018 0.428±0.029 0.942 
average thickness 51.15±2.20 48.94±3.61 0.964 
Nasal 53.60±2.03 51.23±3.70 0.970 
Temporal  50.90±3.77 49.01±4.41 0.889 
Superior 48.75±4.01 48.08±3.88 0.683 
Inferior 51.35±1.94 47.42±4.18 0.997 
IPL     
total volume (mm3) 0.353±0.030 0.357±0.027 0.339 
average thickness 39.40±3.67 39.18±3.27 0.578 
Inferior  39.00±4.92 37.54±3.78 0.862 
Nasal  40.37±3.37 40.66±3.66 0.403 
Superior  37.50±3.63 37.39±3.68 0.534 
Temporal  40.71±4.73 41.10±3.28 0.369 
OPL    
total volume (mm3) 0.294±0.373 0.301±0.037 0.031 
average thickness 31.32±3.40 32.10±3.89 0.267 
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Inferior  30.91±3.38 31.51±4.68 0.410 
Nasal  33.87±6.19 35.33±7.42 0.620 
Superior  30.16±3.36 30.65±3.42 0.442 
Temporal  30.33±3.54 30.88±3.50 0.483 
INL    
total volume (mm3) 0.338±0.020 0.348±0.028 0.124 
average thickness 38.08±1.39 38.54±3.13 0.312 
Inferior  37.54±1.23 38.45±3.04 0.158 
Nasal  39.70±1.55 39.67±4.66 0.510 
Superior  38.08±1.81 38.70±3.18 0.645 
Temporal  37.00±2.83 37.34±3.37 0.372 
ONL    
total volume (mm3) 0.679±0.066 0.671±0.067 0.644 
average thickness 67.09±7.02 66.48±7.04 0.604 
Inferior  64.16±7.38 64.00±7.94 0.529 
Nasal  67.92±8.66 64.51±8.97 0.877 
Superior  68.08±7.14 68.34±6.63 0.453 
Temporal  68.20±7.17 69.09±7.68 0.361 
Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform 
layer; mRNFL, macular retinal nerve fiber layer; ONL, outer nuclear layer; OPL, outer 
plexiform layer; pRNFL, peripapillary retinal nerve fiber layer. 
NOTE. All measurements, for each layer, are acquired from all radial quadrants from the 
ETDRS circular grid, with a 3.45-mm diameter centered on the fovea. Data from both eyes 
are averaged. Values are mean ± SD. All values are in micrometer (mm), unless otherwise 
indicated. 
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Table 4. Change over 27 Months by Groups  
 
Location 
Pre-Clinical AD 
(N=15) 
Healthy Controls 
(N=41) 
 
p-value 
Effect Size 
(Cohen’s d) 
mRNFL     
Volume (mm3) -0.032±0.003 -0.019±0.003 0.050 0.550 
Average  -4.45±3.68 -3.26±3.94 0.448 0.3072 
Inferior -4.45±3.314 -3.09±4.323 0.656 0.3352 
Superior -5.10±3.671 -4.50±4.845 0.348 0.1318 
Nasal -4.50±3.801 -2.41±4.416 0.196 0.4917 
Temporal -3.75±3.936 -3.04±2.212 0.77 0.2528 
pRNFL     
Average  -3.389±2.058 -1.181±4.057 0.060 0.605 
Inferior -1.39±6.22 1.63±9.10 0.386 0.357 
Superior -3.33±11.92 -1.41±14.10 0.631 0.141 
Nasal 1.67±5.97 3.81±7.79 0.381 0.290 
Temporal -1.04±4.13 0.18±4.51 0.400 0.276 
GCL     
Volume (mm3) -0.016±0.016 -0.011±0.019 0.206 0.29 
Average  -1.96±2.59 -1.34±3.03 0.590 0.209 
Inferior -2.4±2.97 -0.86±3.38 0.091 0.464 
Superior -1.0±3.51 -1.43±4.18 0.614 0.107 
Nasal -0.65±3.54 -0.05±3.54 0.321 0.166 
Temporal -3.8±2.87 -3.02±3.83 0.590 0.210 
OPL     
Volume (mm3) 0.017±0.04 -0.003±0.032 0.965 0.603 
Average  0.843±-3.05 -0.605±2.89 0.932 0.495 
Inferior 0.75±3.51 -0.84±2.59 0.956 0.566 
Superior 0.5±3.37 -0.23±3.57 0.262 0.208 
Nasal -0.83±4.88 -1.77±6.85 0.329 0.144 
Temporal 2.95±4.31 0.43±4.53 0.040 0.562 
ONL     
Volume (mm3) -0.029±0.030 -0.007±0.035 0.026 0.646 
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Average  -1.61±2.86 -0.068±3.39 0.077 0.469 
Inferior -2.25±5.66 0.84±4.54 0.026 0.644 
Superior -1.70±2.60 -1.43±3.73 0.405 0.078 
Nasal 0.87±3.58 2.92±7.27 0.176 0.305 
Temporal -3.37±7.62 -2.60±5.52 0.347 0.128 
IPL     
Volume (mm3) -0.014±0.015 -0.006±0.011 0.020 0.686 
Average  -1.80±1.91 -1.06±1.66 0.099 0.427 
Inferior -2.41±3.32 -0.84±2.17 0.028 0.638 
Superior -1.91±1.50 -1.06±2.49 0.133 0.368 
Nasal -0.95±2.23 -1.07±2.011 0.567 0.055 
Temporal -1.91±2.11 -1.29±2.57 0.22 0.250 
INL     
Volume (mm3) 0.004±0.019 0.001±0.022 0.64 0.12 
Average  2.04±2.14 2.30±5.50 0.43 0.276 
Inferior 2.04±2.32 0.19±2.67 0.98 0.708 
Superior 0.33±1.91 0.011±2.38 0.665 0.140 
Nasal 0±1.97 0.47±3.94 0.34 0.131 
Temporal 0.70±2.75 0.39±2.25 0.655 0.131 
 Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform 
layer; mRNFL, macular retinal nerve fiber layer; ONL, outer nuclear layer; OPL, outer 
plexiform layer; pRNFL, peripapillary retinal nerve fiber layer.                                        
NOTE. All measurements, for each layer, are acquired from all radial quadrants from the 
(ETDRS) circular grid, with a 3.45-mm diameter centered on the fovea. Data from both 
eyes are averaged. Values are mean ± SD, unless otherwise indicated. All values are in 
micrometer (mm), unless otherwise indicated.  
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Table 5. Multivariate linear regression model of volume (mm3), for different 
locations 
Location Coef. Neocortex 
SUVr 
Neocortex  
SUVr P-Value 
Coef. Age Age P-Value 
Volume  
   
mRNFL -0.228 0.041 0.00009 0.024 
GCL -0.003 0.78 -0.0008 0.05 
OPL 2.05 0.84 -0.034 0.691 
ONL -0.0267 0.423 0.00026 0.834 
IPL -0.014 0.144 -0.0034 0.196 
INL 0.026 0.08 -0.005 0.26 
 
Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform 
layer; mRNFL, macular retinal nerve fiber layer; ONL, outer nuclear layer; OPL, outer 
plexiform layer; PET, positron emission tomography; pRNFL, peripapillary retinal nerve 
fiber layer; SUVr, standardized 
uptake value ratio. 
NOTE.Values are in cubic millimeter (mm3) for the coefficients. Controlling for 
participants’ age, with total neocortical PETamyloid ligand binding (SUVr) entered as the 
dependent measure.
 138 
 
 
Fig. 1. Representative cross-sectional OCT image through macular region, with the fovea in 
the center (green line). Labels are shown for the RNFL, GCL, and IPL. The mean macular 
thickness of each retinal layer was measured within four sectors (superior, inferior, nasal, and 
temporal), extending 3.45 mm from the center of the fovea, leading to a macular volume 
measurement for each retinal layer. Mean volumes (mm3) for each layer and thickness (mm) 
for each quadrant (right and left eyes averaged) were computed for both the baseline and the 
27-month time points. Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; 
OCT, optical coherence tomography; RNFL, retinal nerve fiber layer. 
 
 
Linear Fit: Adj R2 = 0.106, ρ < 0.017 
Fig. 2.  Relationship between macular RNFL volume change over 27 months 
and total neurocortical amyloid aggregation (18F-florbetapir PET SUVr) at 
end of study. Abbreviations: PET, positron emission tomography; RNFL, 
retinal nerve fiber layer; SUVr, standard uptake value ratio. 
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Linear Fit: Adj R2 = 0.098, ρ < 0.037 (1-tailed) 
 
Fig. 3.  Relationship between macular RNFL volume change over 27 months and performance 
on a measure of audiovisual integration efficiency (“McGurk Task”[60]). Abbreviation: 
RNFL, retinal nerve fiber layer. 
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Abstract  
 
Introduction: Retinal and cerebral microvasculature share similar embryological 
origins, anatomical features and physiological properties; and reduced retinal blood 
flow has been reported previously in mild cognitive impairment (MCI) and 
Alzheimer’s disease (AD), relying on both Doppler ultrasonography and optical 
coherence tomography angiography (OCTA) imaging technologies.  The present study 
relies on OCTA to explore this same question in the preclinical AD stage of the 
disease. 
 
Methods: Forty-eight adults (mean age = 68.76 years) with well-established risk 
factors for AD were recruited. Florbetapir amyloid PET scans were obtained and 
neocortical PET and standardized uptake value ratios (SUVr) threshold of 1.1 or 
greater was used to identify individuals with preclinical AD.  Retinal OCTA images 
were captured using an AngioVue system (Optovue, Fremont, CA, USA), and the Df 
was measured in linearized superficial microvascular plexus images to measure the 
space-filling linear extension of the large vessels. 
 
Results: The mean Df of preclinical AD subjects (N = 10) was significantly lower 
(ρ=0.005), with substantially greater variability, than that of healthy controls in the 
macular region (N = 28) (heteroscedastic Student’s t-test, 2-tailed). For the 
peripapillary region there was no significant difference (ρ=0.12) between both groups. 
 
Conclusion: Our findings suggest that individuals at high-risk for preclinical AD have 
less density and complexity of retinal microvascular networks in the superficial 
vascular plexus in the macular region than healthy controls. Retinal vascular 
distribution and blood flow are already altered during the very earliest stages of AD. 
 
 
Keywords:  angio-OCT; retinal; blood flow; preclinical; Alzheimer’s; fractal 
dimension 
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Introduction 
 
 
The co-occurrence of various cerebrovascular changes and Alzheimer’s 
disease (AD) is both well established and interdependent (1, 2).  Whereas unimpaired 
cerebral blood flow (CBF) supports healthy neural activity and function, reduced CBF 
has been repeatedly observed in mild cognitive impairment (MCI) (3-9). Moreover, 
vascular density is significantly reduced, specifically in the basal forebrain region and 
the hippocampus of AD brains (10), and the capillary ultrastructure in the limbic 
cingulate cortex is severely compromised (11).  Such cerebral capillary damage can 
lead to pathophysiological consequences, such as compromised nutrient transport, 
insufficient neuronal metabolism and subsequent cognitive disturbances; it should be 
considered a significant factor in the development of AD (11-14).  AD has been 
associated with decreased anatomic complexity (e.g., tortuosity) of the cerebral 
vasculature, with venous collagenosis, string vessels (capillary remnants), decreased 
vascular density, and with concomitant microembolic brain injuries (15).  
Diminished or altered CBF has not been conclusively shown to occur in the 
preclinical stage of AD following National Institute on Aging – Alzheimer’s 
Association (NIA-AA) criteria (16), and AD-related perfusion studies are largely 
restricted to correlating CBF with genetic and cognitive factors (17). For example, 
Okonkwo and colleagues (18) reported decreased CBF in right superior and middle 
frontal cortices for middle-aged adults with familial history of AD compared to age-
matched cognitively normal subjects.  Moreover, relative decrements in CBF were 
associated with modest impairments in memory function (18, 19) and general 
cognitive performance (20,21).  Several recent publications have suggested specific 
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cerebral perfusion markers as potential indicators for amyloidosis and early disease 
detection (22-24).  
The measurement of blood flow in the retina is likely to be very closely related 
to, and indicative of, neocortical blood flow.  Retinal angiographic imaging allows for 
non-invasive access to the microcirculation, and the retinal vasculature shares similar 
embryological origin, anatomical features, and physiology with the cerebral 
vasculature (25-30).  Reduced retinal blood flow has been reported in MCI and AD 
patients using Doppler methodology (31,32), and such retinal abnormalities as 
vascular attenuation, increased variability in vessel widths, reduced complexity of the 
branching pattern and less tortuous venules have been found in AD (33). 
With very recent advances in angiographic optical coherence tomography 
imaging (OCTA), the retinal microvasculature can now be visualized without the need 
for intravenous administration of a contrast dye agent (34), to provide a range of 
measures such as the width of the lumen of vessels as small as 6-8 µm, vessel 
tortuosity and bifurcations, and these images can be subjected to a broad array of 
analytic approaches. OCTA has shown potential efficacy in the evaluation of common 
ophthalmologic diseases (35). In diabetic retinopathy, the foveal avascular zone (FAZ) 
and parafoveal vessel density provide a detailed view of the retinal vasculature and 
have been measured with high reproducibility by OCTA in both superficial and deep 
plexus (36). OCTA can also detect changes in choroidal blood vessel flow in age 
related macular degeneration.  Narrowing of central retinal venous column diameter 
has been reported in AD and MCI (31,32). 
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Although there are many potential approaches to the extraction of important 
data from highly complex OCTA retinal images, one approach that relies of fractal 
geometry and the computation of fractal dimension (Df) values to objectively score 
the complexity and density of vascular branching, has already been used with apparent 
success.  Using this very approach, Jiang and colleagues reported microvascular loss, 
beyond what is seen as a consequence of normal aging, in patients with MCI and AD 
(37).  Since there remains a clear need for reliable, non-invasive techniques for 
screening potential high-risk individuals who may be in the earliest stages of AD, we 
decided to adopt this same analytic approach to explore retinal blood flow changes in 
the preclinical stage of AD.  We have not been able to identify any other published 
literature that has addressed this question at such an early stage of the disease process.   
 
 
 
 
 
. 
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Methods 
 
Participants 
A total of Fifty-six adults aged between 55 and 75 years (mean age = 65.36 
years old) with two well-established risk factors for AD, namely, a self-reported first-
degree family history of the disease and self-identification of subjective memory 
concerns, were recruited using a selection process described previously (38).  All 
participants underwent a detailed medical screening interview. Exclusion criteria 
included a diagnosis of MCI or AD following NIA-AA diagnostic criteria (39,40), 
history of neurological or psychiatric disorder, any significant systemic illness or 
unstable medical condition (e.g., active cardiovascular disease), and current use of any 
medications known to affect cognition (e.g., use of sedative narcotics). Subjects with 
histories of cataract surgery, corneal LASIK surgery, age-related macular 
degeneration, glaucoma, diabetic retinopathy or subjects with known ophthalmic 
pathology were excluded.  
Inclusion criteria included a score on the mini-mental state examination 
(MMSE) > 27 and performance within normal limits on the International Shopping 
List Test (ISLT; www.cogstate.com) as a measure of verbal episodic memory; and the 
Memory Complaint Questionnaire (MAC-Q) (41,42). All participants live 
independently, most were engaged in full-time or part time employment, and many 
were caretakers for a parent with AD.  
From this larger sample, we identified 15 participants who were categorized as 
presenting with preclinical stage disease based on evidence of elevated neocortical 
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beta-amyloid burden as determined by PET amyloid imaging (16, 39). The study was 
approved by and complied with the regulations of Rhode Island Hospital’s 
Institutional Review Board, and all participants provided written informed consent in 
accordance with the Declaration of Helsinki, and this study complied with HIPAA 
regulations. 
 
Aβ PET imaging 
To assess neocortical amyloid burden, all participants had an Aβ PET scan. A 
370MBq (10 mCi 1/2 10%) bolus injection of 18F-florbetapir was administered 
intravenously. Approximately 50 minutes’ post-injection, a 20-minute PET scan was 
performed with head CT scan for attenuation correction purposes. Images were 
obtained using a 128X128 matrix and reconstructed using iterative or row action 
maximization likelihood algorithms. PET standardized uptake value (SUV) data were 
summed and normalized to the whole cerebellum SUV, resulting in a region-to-
cerebellum ratio termed SUV ratio (SUVr).  
A SUVr threshold of 1.1 or greater was used to discriminate between Aβ+ and Aβ-. 
These SUVr calculations were performed using the MIMneuro software, with a 
normative database of 74 healthy normal individuals (48 males, 26 females), aged 
between 18–50 years, who all had negative amyloid scans on visual assessment (43). 
For all cases, Aβ positivity was confirmed by consensus over-read by two board-
certified radiologists who were also board certified in nuclear medicine 
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Angio-OCT 
 
OCTA images were captured using AngioVue (Optovue, Fremont, CA, USA). 
OCTA volume scans were obtained horizontally and vertically to decrease motion 
artifacts and fixation changes. Split-spectrum amplitude-decorrelation angiography 
was used to detect flow and produce OCTA images and en face sections. A 3x3-
volume scan centered on the fovea and in the optic nerve were obtained with an A-
scan rate of 70kHz. Each volume scan consists of 304x304 A-scans with 2 consecutive 
B-scans at each position. Two right-angled OCT-A volume scans are performed for 
orthogonal registration to correct for motion artefacts.  Split-spectrum amplitude-
decorrelation angiography was used to detect flow and produce OCTA images and en 
face sections. We selected the right eye OCTA of each participant for the fovea and 
optic nerve images to realize the Df analysis, using the superficial microvascular 
plexus images (3 µm below internal limiting membrane and 15 µm below inner 
boundary of inner plexiform layer). 
The Df was measured in linearized vascular images in order to measure the 
space-filling linear extension of the vessels. Df was estimated with a computer 
program implementing the method of boxcounting. With this method, the image is 
overlaid with series of square boxes of decreasing size (s = 512, 256, 128, . . . 1, where 
s denotes a single pixel), and the number of boxes [N(s)] containing at least one black 
pixel is counted. The negative value of the least squares regression slope of the plot of 
log N(s) versus log s yields Df (44). The images were analyzed removing the small 
vessels, keeping only vessels with a diameter of more or equal to 25 μm (37). 
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Statistical Analysis 
Demographic characteristics of the preclinical AD and healthy controls 
subjects were compared (Tables 1 and 2) for those individuals with good quality 
OCTA images in the macular region (N=38) and peripapillary region (N=48). To 
compare the variables Sex and APOE, the freq procedure was done in SAS and the 
Fisher’s exact test was used due to the small sample sizes.  For all the other 
demographic and cognitive variables: Age, Education, Florbetapir PET SUVr, MAC-
Q, MMSE and ISLT Total recall, the means ± SD were computed for each group and 
t-tests were used to identify group differences. 
For each individual, the Df (with a grid size of 64 pixels) for the superficial 
vascular plexi, in the macular (centered on the fovea) and peripapillary (centered on 
optic nerve head) regions of the right eye retinas, were computed (mean and standard 
deviation (SD) of the measurements). Only good quality images were included (that is, 
those that were free of substantial imaging artefacts), resulting in 10 participants for 
the preclinical AD group and 28 healthy controls for the macular region analyses, and 
an additional 10 healthy control cases for the peripapillary region analyses.  The 
normality of the Df measurement distributions, for both groups, were verified with the 
Shapiro-Wilks test, with normally distributed data then analyzed using the t-test 
pooled method and non-normally distributed data analyzed using the Satterthwaite 
method.  
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Results 
 
Of the 38 participants with high-quality macular OCTA images, there were no 
significant differences between Aβ+ and Aβ- groups with respect to sex (ρ =0.69). 
Likewise, there were no group differences in the proportion of individuals with the 
APOE Ɛ4 genetic risk marker for AD (ρ =0.269). The mean age of the total sample 
was 69.36 years old and this sample had an average of 17.25 years of education with 
no education difference between groups (ρ =0.64). All relevant demographic 
information, for both groups, are provided below in Table 1. There were no group 
differences with respect to general cognitive function or subjective memory 
complaints (MMSE and MAC-Q) nor on a performance measure of episodic verbal 
memory (ISLT).  By definition, both groups significantly differed with respect to 
neocortical amyloid aggregation as measured via PET imaging (ρ = 0.000).  
-------------------------------------------- 
Insert Table 1 About Here 
-------------------------------------------- 
 
Of the 48 participants with high-quality peripapillary OCTA images (Table 2), 
there were similarly no significant differences between Aβ+ and Aβ-  groups with 
respect to sex (sex (ρ =0.281).  Likewise, there were no group differences in the 
proportion of individuals with the APOE Ɛ4 genetic risk marker for AD (ρ =0.151). 
The mean age of the total sample was 69.76 years old and this sample had an average 
of 17.45 years of education with no education difference between groups (ρ =0.789).  
There were no group differences with respect to general cognitive function or 
subjective memory complaints (MMSE and MAC-Q) nor on a performance measure 
of episodic verbal memory (ISLT).  By definition, both groups significantly differed 
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with respect to neocortical amyloid aggregation as measured via PET imaging (ρ = 
0.000).  
-------------------------------------------- 
Insert Table 2 About Here 
-------------------------------------------- 
 
Results of the region-based fractal analysis (Df values) of linearized vascular 
patterns extracted from OCTA of preclinical AD and healthy controls, are summarized 
in Figure 1 for the macular region and Figure 2 for the peripapillary region. In the 
macular region, mean ± SD of healthy controls was 1.5896± 0.0999 and of preclinical 
AD was 1.3860±0.1799. The mean Df in the macula of preclinical subjects (N=10) is 
both significantly lower (ρ=0.005), and there is clearly greater variability in these 
measurements, as compared to the healthy controls (N=28). 
-------------------------------------------- 
Insert Figure 1 About Here 
-------------------------------------------- 
 
In the peripapillary region, mean ± SD of healthy controls was 1.4290± 0.0975 
and of preclinical AD was 1.3744±0.1064. The mean Df of preclinical subjects (N=10) 
in the peripapillary is not significantly different (ρ=0.12) than that of healthy controls 
(N=38). 
-------------------------------------------- 
Insert Figure 2 About Here 
-------------------------------------------- 
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Conclusion 
 
The observed decrement in vascular bed density and complexity, as measured 
by the computation of the Df for each image of the superficial and/or deep vascular 
plexi, was reported to be reduced by 0.05 in AD and 0.03 in MCI, compared to elderly 
controls (37).  We have found that at any even early stage of disease progression (in 
preclinical AD) the microvascular network loss in the superficial capillary plexus for 
the macular region was similarly reduced compared to healthy controls (ρ=0.005) (see 
examples in Figure 3).  
-------------------------------------------- 
Insert Figure 3 About Here 
-------------------------------------------- 
 
 These results fit nicely with our recent report that a volume reduction in the 
macular retinal nerve fiber layer (RNFL) appears to be the location of the earliest 
observable structural (retinal cell layer) change in the preclinical stage of AD (45).  As 
we previously described, the macular region of the retina is physiologically very active 
in healthy normal eyes (46), and this “hyperexcitation” might be diminishing in the 
preclinical stage of AD.  Postmortem histological studies have revealed prominent 
pathological alteration of retinal ganglion cells (RGCs) in the macular region in 
clinical AD patients (47,48).  However, in the preclinical disease stage we may be 
observing either demyelination or loss of axons in the RNFL, prior to any loss of cell 
bodies in the ganglion cell layer (GCL) (45). 
The superficial microvascular plexus (SVP) is supplied by the central retinal artery 
and composed of larger arteries, arterioles, capillaries, venules and veins that primarily 
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course through the GCL (49).  Primate histology demonstrated that the SVP supplies 
all other vascular plexi through vertical pre-capillary arterial segments, which 
typically ascend to the nerve fiber layers and descend to the deeper layers (50,51).  
Reduced vascular density in the SVP likely leads to degradation in blood flow 
throughout the in other parts of the retina and, hence, might directly contribute to 
continued axonal loss as well as GCL thinning in AD.  
This is a small experimental study with a limited sample size, but we believe 
that these results fit nicely with our emerging understanding of early retinal changes in 
the preclinical stage of AD, and we are now planning to replicate this work in a much 
larger longitudinal natural history study, with a participant cohort that will span the 
entire spectrum of the AD severity range.  
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Table 1. Demographic Characteristics for Subjects with Acceptable Quality OCTA 
Imaging in the Macular Region 
 
 Main Outcome Full sample 
(n = 38) 
Aβ+ (n=10) Aβ- (n=28)  
  N(%) N(%) N(%) ρ 
Sex Number of 
female 
27 (71.34) 8 (80) 19 (67.86) .69 
APOE Number of Ɛ4 
carriers 
19 (50) 7 (70) 12 (42.86) .269 
  Mean (SD) Mean (SD) Mean (SD) ρ 
Age Number of 
years 
69.36 (5.20) 71.4 (5.66) 68.64 (4.93) .153 
Education Number of 
years 
17.25 (2.71) 17.12 (2.47) 17.6 (3.43) .64 
Florbetapir 
PET SUVr 
Standardized 
Uptake Value 
ratio 
1.03 (0.17) 1.29 (0.13) 0.94 (0.07) .000 
MAC-Q Total Score 25.5 (3.20) 26.6 (2.36) 25.10 (3.40) .21 
MMSE Total Score 29.10 (1.07) 28.7 (1.25) 29.25 (0.98) .162 
ISLT Total 
Recall 
Total words 
recalled 
25.92 (4.23) 24.10 (4.7) 26.78 (3.84) .080 
 
*Note: SUVr = standardized uptake value ratio; MAC-Q= Memory Complaint Questionnaire; 
MMSE = Mini Mental State Examination; ISLT = International Shopping List Test 
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Table 2. Demographic Characteristics for Subjects with Acceptable Quality OCTA 
Imaging in the Peripapillary Region 
 
 Main Outcome Full sample 
(n = 48) 
Aβ+ (n=10) Aβ- (n=38)  
  N(%) N(%) N(%) ρ 
Sex Number of 
female 
30 (62.5) 8 (80) 22 (57.89) .281 
APOE Number of Ɛ4 
carriers 
24 (50) 7 (70) 15 (39.47) .151 
  Mean (SD) Mean (SD) Mean (SD) ρ 
Age Number of years 68.76 (5.30) 71.4 (5.66) 68.07 (4.95) .104 
Education Number of years 17.45 (2.82) 17.12 (2.47) 17.32 (2.52) .798 
Florbetapir 
PET SUVr 
Standardized 
Uptake Value 
ratio 
1.01 (0.16) 1.29 (0.13) 0.94 (0.07) .000 
MAC-Q Total Score 26.32 (3.85) 26.6 (2.36) 25.97 (4.01) .273 
MMSE Total Score 29.16 (1.0) 28.7 (1.25) 29.27 (0.93) .118 
ISLT 
Total 
Recall 
Total words 
recalled 
25.78 (4.31) 24.10 (4.7) 25.89 (4.04) .233 
 
*Note: SUVr = standardized uptake value ratio; MAC-Q= Memory Complaint Questionnaire; 
MMSE = Mini Mental State Examination; ISLT = International Shopping List Test 
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Figure 1. Mean, range and standard deviation’s (SD) for fractal dimension (Df) 
measurements, in the superficial vascular plexus within the macular region, for 
individuals with elevated (preclinical AD, N = 10) vs. normal neocortical amyloid 
aggregation (healthy controls, N = 28). 
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Figure 2. Mean, range and standard deviation’s (SD) for fractal dimension (Df) 
measurements, in the superficial vascular plexus within the peripapillary region, for 
individuals with elevated (preclinical AD, N = 10) vs. normal neocortical amyloid 
aggregation (healthy controls, N = 38). 
 
 
 
 
 
 163 
 
Figure 3(a). Example of a linearized OCTA image for the superficial vascular plexus 
from an individual who meets amyloid PET imaging criteria for preclinical AD 
 
  
 
 
 
Figure 3(b). Example of a linearized OCTA image for the superficial vscular plexus 
from a healthy control individual 
 
 
 
